



HAL
open science

Metallo- β -lactamases

Elsa Denakpo, Guillaume Arlet, Alain Philippon, Bogdan Iorga

► **To cite this version:**

Elsa Denakpo, Guillaume Arlet, Alain Philippon, Bogdan Iorga. Metallo- β -lactamases. Metalloenzymes, Elsevier, pp.157-184, 2024, 10.1016/B978-0-12-823974-2.00001-2 . hal-04204861

HAL Id: hal-04204861

<https://hal.science/hal-04204861>

Submitted on 12 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Chapter 3.2

Metallo- β -lactamases

Elsa Denakpo,¹ Guillaume Arlet,² Alain Philippon,³ Bogdan I. Iorga¹

¹ Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, Gif-sur-Yvette, France

² Sorbonne Université, U1135, CIMI-Paris, Paris, France

³ Faculté de Médecine, Bactériologie, Université de Paris, Paris, France

[NON PRINT ITEMS]

Abstract:

Metallo- β -lactamases (MBLs) are a class of enzymes that are produced by a variety of bacterial species and are responsible for conferring resistance to a broad range of β -lactam antibiotics, including carbapenems, which are often considered the “last line of defense” against antibiotic-resistant infections. The spread of MBL-producing organisms and the limited treatment options available for infections caused by these organisms represent serious challenges that they pose to public health. The chapter will cover the current state of research on MBLs, including the structure-function relationship, the genetic diversity, the mechanism of resistance and the development of inhibitors in this field.

Key Words:

metallo- β -lactamases ; carbapenemases ; inhibitors ; antibiotic resistance ; Gram-negative bacteria

[H1 Introduction]

Metallo- β -lactamases (MBLs) are a major public health concern as they are able to hydrolyze most β -lactam antibiotics, including penicillins, cephalosporins, and carbapenems, leading to treatment failure and increased morbidity and mortality. These enzymes have been identified in a wide range of Gram-negative and Gram-positive bacteria, and have been reported in many parts of the world. The emergence and spread of MBL-producing bacteria have led to a rise in treatment-resistant infections and a decrease in the effectiveness of antibiotics.

β -Lactamases can be classified in two different ways, according to their sequence similarity (molecular classification) or to the activity profile (functional classification). The former is known as Ambler classification (1, 2) and organizes the β -lactamases in classes A, C and D, which are serine- β -lactamases (SBLs), and class B, which are MBLs. The MBLs are further organized in three subclasses, B1, B2 and B3 (Figure 3.2.1). The latter is a functional classification (3, 4), based on the specific hydrolysis profile against different β -lactam substrates.


High quality and comprehensive reviews focused on clinically relevant β -lactamases were published over the years, with a special focus on carbapenemases (4-11) or on MBLs (12-27).

[H1 Structure and function of metallo- β -lactamases]

[H2 Phylogenetic comparison and evolution]

The MBLs are organized phylogenically in three distinct clusters, which correspond to subclasses B1, B2 and B3 (Figure 3.2.1). Subclasses B1 and B2 form a distinct phylogenetic group (28), separated from the cluster B3 by an intermediary region with enzymes possessing variable active sites and mixed substrate hydrolysis profiles (Figure 3.2.1). A phylogenetic comparison of all members of the MBL superfamily suggested that the β -lactamase activity appeared and evolved separately in the B1+B2 and B3 groups (27, 29). A recent study evidenced the evolutionary traits acquired by several clinically-relevant MBLs in order to adapt to their native environment, depending if they are soluble or membrane-bound proteins. An important factor influencing this evolution is the amount of metal available in the cell under zinc starvation conditions (30).

An *in-silico* analysis based on protein sequence similarity networks (SSNs) applied to the superfamily of MBLs, combined with traditional cladistic and phenetic phylogenetic analysis, evidenced the zinc-coordinating motifs that are specific for each enzymatic reaction. Additionally, the local network interconnectivity was measured using the neighborhood connectivity coloring to detect new protein families within the SSN clusters. This approach evidenced the important number of unexplored protein families in this superfamily (31).




*** Insert Figure 3.2.1 ***

Caption: Phylogenetic tree of MBLs. The enzymes belonging to subclasses B1, B2 and B3 are colored in orange, blue and magenta, respectively. The plasmidic MBLs are labeled with a *, and those situated in the intermediary region are highlighted in bold. The tree was generated using SeaView (32) and the phylogram generated using FigTree (version 1.4.3).

Credit: The authors (Elsa Denakpo, Guillaume Arlet, Alain Philippon, Bogdan I. Iorga)

[H2 Primary structure/sequence analysis]

The sequences of MBLs are not well conserved, with sequence identities as low as 10 % for the most distant members. The most conserved residues are those coordinating the zinc ions (Figure 3.2.2). The B1 subclass is characterized by the motifs $^{116}\text{HxHxDx}$, ^{196}H , ^{221}C and ^{263}H . The motifs present in the subclass B2 are very similar, differing only at the residue in position 116: $^{116}\text{NxHxDx}$, ^{196}H , ^{221}C and ^{263}H . The differences are more significant in the subclass B3. First, the Cys residue in position 221 is absent, and replaced by a His in position 121. Second, most sequences have the motif $^{116}\text{HxHxDH}$, but there are some notable exceptions, with some different motifs: $^{116}\text{QxHxDH}$ (GOB, CPS, ESP, PLN, SIQ, LRA12, LRA17, LRA19 and PEDO-1/2 families), $^{116}\text{ExHxDH}$ (SIE and SSE families) and $^{116}\text{HxRxDQ}$ (SPR, CSR and SER families). For the B3 subclass it was proposed to use the active site amino acid changes to distinguish the variants (i.e., B3-RQK, B3-Q, B3-E) (33).



*** Insert Figure 3.2.2 ***

Caption: Residue conservation in the sequences of MBLs in the regions neighboring the zinc-coordinating residues (positions 116, 118, 120, 196, 221 and 263 for subclasses B1 and B2, and positions 116, 118, 120, 121, 196 and 263 for subclass B3). The image was generated with WebLogo version 3 (34).

Credit: The authors (Elsa Denakpo, Guillaume Arlet, Alain Philippon, Bogdan I. Iorga)

A standard numbering scheme for MBLs (named BBL) was developed in 2001 and updated in 2004 (35, 36). This scheme is based on the structural alignment of representative members of each subclass and allows the comparison of residues from equivalent positions, which otherwise would have different numbers, specific to each family. The representative MBLs from each subclass (B1, B2 and B3) are presented in Table 1.

[H2 Mutations and spectrum of activity]

Historically, the class A molecular β -lactamases, particularly TEM enzymes, constituted an excellent model of molecular evolution when the first third-generation cephalosporins (ceftazidime and cefotaxime) were introduced into clinical practice in the 1980s. The substitution of certain amino acids in ESBLs (Extended-Spectrum Beta-Lactamases) such as Glu104Lys, Arg164Ser/His, Ala237Thr, Gly238Ser, Glu240Lys/Arg led to the extension of the spectrum due to an improved affinity (37, 38). On the other hand, other substitutions (Met69Leu/Val/Ile, Trp165Arg, Met182Thr, Arg244Cys/Ser/Thr, Val261Ile, Arg275Leu/Gln, Asn276Asp) in the same type of enzyme had an opposite effect, namely a decrease in affinity and therefore resistance to inhibitors such as clavulanic acid and sulbactam (defined as IRT, Inhibitor Resistant TEM) (39).

The evolutionary potential of MBLs appears to be less significant if judged by the extended inactivation spectrum of these enzymes with respect to β -lactams (except for monobactams such as aztreonam), including carbapenems and cefepime, and on the other hand, by a smaller number of variants, especially in transferable MBLs such as IMP, NDM and VIM enzymes, which are mainly involved in clinical medicine. Thus, 249 variants have been identified for TEM type enzymes, 48 for NDM, 83 for VIM, and 98 for IMP (40). Protein sequence heterogeneity is the lowest in the NDM family, ranging from 74 % to 100 %, and several substitution locations (one to three amino acids) have been identified without notable differences in β -lactam resistance levels and kinetic constants (P28A, V88L, D95N, D130G, E152K, M154L, G222D, R264H). Several substitution locations have also been evaluated by directed mutagenesis as indicated in Table 2 for several NDM type enzymes, allowing for a better understanding of this enzyme family, including the importance of some amino acids away from the active site (41-46). It is important to emphasize the absence of mutations that generate a higher level of resistance, especially with respect to carbapenems or aztreonam or cefepime.

Regarding the IMP family, protein heterogeneity ranges from 80 % to 100 %, and several substitutions (in positions 59, 67, 115, 119, 120, 121, 218, 233, 262) have been identified without notable differences in resistance to β -lactams, including carbapenems (47-52).

Several sites tested by directed mutagenesis were also evaluated (Table 3). The potential for expanding the spectrum remains limited again in the absence of mutants generating a higher level of resistance, particularly against carbapenems or aztreonam (47, 53-56).

The VIM family consists of 80 variants, with a sequence identity ranging from 75 % to 100 % and which can be grouped in at least three clusters, including two dominant ones. The

evolutionary potential of this family towards increased resistance to some β -lactams is again limited. This is true for the naturally occurring mutants, which are observed in clinic, but also for synthetic mutants obtained through directed mutagenesis (57-66).

The hyperproduction of the enzyme induced by a strong promoter, obtained by mutation, is a well-known mechanism reported in molecular classes A and C β -lactamases. However, this mechanism remains little described in transferable MBLs (e.g. IMP, NDM, or VIM) (67-73).

Table 1. Representative class B β -lactamases

Sub-class	Metallo- β -lactamase	Origin of name ^a	Accession	Gene ^b	Organism	Number of residues	References
B1	AFM-1	<i>Alcaligenes faecalis</i> Metallo- β -lactamase	AYV97588	P	<i>Alcaligenes faecalis</i>	267	(74)
B1	ANA-1	<i>Anaeromyxobacter</i> sp.	WP_041449074	CHR	<i>Anaeromyxobacter</i> sp.	255	(75)
B1	BcII-1	<i>Bacillus cereus</i> type II	AAA22276	CHR	<i>Bacillus cereus</i>	257	(76)
B1	BIM-1	Belem imipenemase	ANY85569	In	<i>Pseudomonas putida</i>	245	–
B1	BlaB-1	Beta-lactamase class B	AAF89154	CHR	<i>Elizabethkingia meningoseptica</i>	249	(77)
B1	CAM-1	Central Alberta Metallo- β -lactamase	AVX51087	CHR	<i>Pseudomonas aeruginosa</i>	241	(78)
B1	CEMC19-1	Name of clone	Name of clone	CHR	Uncultured bacteria	252	(79)
B1	CfiA	Cefoxitin-imipenem-hydrolyzing enzyme	AAA22907	CHR	<i>Bacteroides fragilis</i>	249	(80, 81)
B1	CGB-1	<i>Chryseobacterium gleum</i> class B	AAL55263	CHR	<i>Chryseobacterium gleum</i>	242	(82)
B1	CrxA-1	Carbapenem resistant <i>B. xylanisolvens</i>	MBS5055441		<i>Bacteroides xylanisolvens</i>	250	(83)
B1	CX1-1	Name of clone	AGU01687	CHR	Uncultured bacteria	246	(84)
B1	DIM-1	Dutch imipenemase	AGC92784	P, In	<i>Pseudomonas stutzeri</i>	251	(85)
B1	EBR-1	<i>Empedobacter brevis</i> resistant	AAN32638	CHR	<i>Empedobacter brevis</i>	235	(86)
B1	ECV-1	<i>Echinicola vietnamensis</i>	AGA78874	CHR	<i>Echinicola vietnamensis</i>	257	(75)
B1	ElBla2	<i>Erythrobacter litoralis</i> Beta-lactamase 2	ABC63608	CHR	<i>Erythrobacter litoralis</i>	261	(87)
B1	FIA-1	<i>Fibrella aestuarina</i>	WP_041258349	CHR	<i>Fibrella aestuarina</i>	249	(75)
B1	FIM-1	Florence imipenemase	AFV91534	ISCR	<i>Pseudomonas aeruginosa</i>	262	(88)
B1	GIM-1	German imipenemase	ALO69078	P, In	<i>Pseudomonas aeruginosa</i>	250	(89)

B1	GMB-1	<u>German Metallo-Beta-lactamase</u>	QKF95688	CHR	<i>Citrobacter freundii</i>	270	(90)
B1	GRD23-1	Name of clone	APR64493	CHR	Uncultured bacteria	241	(91)
B1	HMB-1	<u>Hamburg Metallo-Beta-lactamase</u>	AMY61250	Tn	<i>Pseudomonas aeruginosa</i>	241	(92)
B1	IMP-1	<u>Imipenem-hydrolyzing β-lactamase</u>	ABK27309	Tn, IS	<i>Serratia marcescens</i>	246	(93)
B1	IND-1	<i>Chryseobacterium indologenes</i>	AAD20273	CHR	<i>Chryseobacterium indologenes</i>	239	(94)
B1	JOHN-1	<i>Flavobacterium johnsoniae</i>	AAK38324	CHR	<i>Flavobacterium johnsoniae</i>	248	(95)
B1	KHM-1	<u>Kyorin Health Science MBL1</u>	BAF91108	P	<i>Citrobacter freundii</i>	241	(96)
B1	MOC-1	<u>Myroides odoratus Carbapenemase</u>	ANJ59787	CHR	<i>Myroides odoratus</i>	248	–
B1	MUS-1	<i>Myroides odoratimimus</i>	AAN63647	CHR	<i>Myroides odoratimimus</i>	246	(97)
B1	MYO-1	<i>Myroides odoratimimus</i>	WP_081048762	CHR	<i>Myroides odoratimimus</i>	266	(75)
B1	MYX-1	<i>Myxococcus xanthus</i>	ABF86854	CHR	<i>Myxococcus xanthus</i>	261	(75)
B1	NDM-1	<u>New Delhi Metallo-β-lactamase</u>	AHM26723	P, In	<i>Klebsiella pneumoniae</i>	270	(98)
B1	ORR-1	<i>Ornithobacterium rhinotracheale</i>	WP_109545042	CHR	<i>Ornithobacterium rhinotracheale</i>	255	(75)
B1	PAN-1	<i>Pseudobacteriovorax antillogorgiicola</i>	SMF47935	CHR	<i>Pseudobacteriovorax antillogorgiicola</i>	270	(99)
B1	PEDO-3	<i>Pedobacter roseus</i>	AJP77076	CHR	<i>Pedobacter kyungheensis</i>	237	(100)
B1	PST-1	<i>Pseudomonas stutzeri</i>	WP_043942497	CHR	<i>Stutzerimonas stutzeri</i>	242	(75)
B1	SFB-1	<i>Shewanella frigidimarina</i> <u>Beta-lactamase</u>	AAT90847	CHR	<i>Shewanella frigidimarina</i>	244	(101)
B1	SHD-1	<i>Shewanella denitrificans</i>	ABE54111	CHR	<i>Shewanella denitrificans</i>	269	(75)
B1	SHN-1	<i>Shewanella denitrificans</i>	ABE56430	CHR	<i>Shewanella denitrificans</i>	237	(75)
B1	SIM-1	<u>Seoul imipenemase</u>	AER61546	In	<i>Acinetobacter baumannii</i>	246	(102)
B1	SLB-1	<i>Shewanella livingstonensis</i> <u>Beta-lactamase</u>	AAT90846	CHR	<i>Shewanella livingstonensis</i>	249	(101)
B1	SPM-1	<u>Sao Paulo Metallo-β-lactamase</u>	AAR15341	Tn	<i>Pseudomonas aeruginosa</i>	276	(103)
B1	SPN79-1	Name of clone	APR64486	CHR	<i>Phenylobacterium/Proteobacteria</i>	278	(91)
B1	SPS-1	<i>Sediminispirochaeta smaragdinae</i>	ADK81930	CHR	<i>Sediminispirochaeta smaragdinae</i>	276	(75)

B1	STA-1	<i>Stigmatella aurantiaca</i>	WP_109545039	CHR	<i>Stigmatella aurantiaca</i>	261	(75)
B1	SZM-1	Shenzhen Metallo-β-lactamase	JAPDUI00000000*	CHR	<i>Arenimonas</i> metagenome	231	(104)
B1	TTU-1	<i>Teredinibacter turnerae</i>	ACR12883	CHR	<i>Teredinibacter turnerae</i>	243	(75)
B1	TMB-1	Tripoli Metallo-Beta-lactamase	CBY88906	In	<i>Achromobacter xylosoxidans</i>	245	(105)
B1	TMB-2	Tripoli Metallo-Beta-lactamase	BAM73613	CHR	<i>Acinetobacter courvalinii</i>	245	(106)
B1	TUS-1	<i>Myroides odoratus</i>	EKB08120	CHR	<i>Myroides odoratus</i>	248	(97)
B1	VAM-1	<i>Vibrio alginolyticus</i> Metallo-β-lactamase	QTJ60982	P,In	<i>Vibrio alginolyticus</i>	246	(107, 108)
B1	VIM-1	Verona Imipenemase	CAC35170	In	<i>Pseudomonas aeruginosa/A.denitificans</i>	266	(109)
B1	VMB-1	<i>Vibrio</i> Metallo-Beta-lactamase	QGQ32905	In	<i>Vibrio alginolyticus</i>	247	(110)
B1	VMH-1	<i>Vibrio</i> MetalloHydrolase	ASM98011	CHR	<i>Vibrio vulnificus</i>	281	(111)
B1	WUS-1	Wenzhou Medical University	UPP01678	CHR	<i>Myroides albus</i>	246	(112)
B1	ZHO-1	<i>Zhongshania aliphaticivorans</i>	WP_082793656	CHR	<i>Zhongshania aliphaticivorans</i>	246	(113)
B1	ZOG-1	<i>Zobellia galactanivorans</i>	CAZ94871	CHR	<i>Zobellia galactanivorans</i>	247	(75)
B2	CphA	Carbapenem-hydrolyzing Metallo-β-lactamase	CAA40386	CHR	<i>Aeromonas hydrophila</i>	254	(114)
B2	ImiS (CphA-11)	Imipenemase <i>Aeromonas veronii</i> bv. <i>sobria</i>	CAA71441	CHR	<i>Aeromonas veronii</i> bv. <i>sobria</i>	255	(115)
B2	ImiH (CphA-13)	Imipenemase <i>Aeromonas hydrophila</i>	CAD69003	CHR	<i>Aeromonas hydrophila</i>	254	(116)
B2	CVI-1	<i>Chromobacterium violaceum</i>	WP_164461288	CHR	<i>Chromobacterium violaceum</i>	255	–
B2	PFM-1	<i>Pseudomonas fluorescens</i> Metallo-β-lactamase	QDC33502	CHR	<i>Pseudomonas fluorescens</i> complex	253	(117)
B2	SFH-1	<i>Serratia fonticola</i> carbapenem hydrolase	WP_024531368	CHR	<i>Serratia fonticola</i>	255	(118)
B2	YEM-1	<i>Yersinia mollaretii</i>	CQH06348	CHR	<i>Yersinia mollaretii</i>	246	(119)
B3	AIM-1	Adelaide imipenemase	CAQ53840	IS	<i>Pseudomonas aeruginosa</i>	303	(120)
B3	ALG6-1	Name of clone	APR64488	CHR	Uncultured bacterium	318	(91)

B3	ALG11-1	Name of clone	APR64489	CHR	Uncultured bacterium	295	(91)
B3	AM1-1	Name of clone	AGU01669	CHR	Uncultured bacterium	311	(84)
B3	BJP-1	<i>Bradyrhizobium japonicum</i>	BAC51495	CHR	<i>Bradyrhizobium diazoefficiens</i>	294	(121)
B3	BLEG-1	<i>Bacillus lehensis</i> strain G1	AIC95013	CHR	<i>Alkalihalobacillus lehensis</i>	428	(122)
B3	CAR-1	<i>Erwinia carotovora</i>	AIA71664	CHR	<i>Pectobacterium carotovorum</i>	342	(123)
B3	CAU-1	<i>Caulobacter crescentus</i>	CAC87665	CHR	<i>Caulobacter crescentus</i>	289	(124)
B3	CPS-1	<i>Chryseobacterium piscium</i>	AJP77054	CHR	<i>Chryseobacterium piscium</i>	290	(100)
B3	CRD3-1	Name of clone	APR64487	CHR	Uncultured bacterium	303	(91)
B3	CSR-1	<i>Cronobacter sakazakii</i> resistant	AKE96626	CHR	<i>Cronobacter sakazakii</i>	318	(33)
B3	DHT2-1	Name of clone	APR64485	CHR	Uncultured bacterium	302	(91)
B3	EAM-1	<i>Erythrobacter aquimaris</i> Metallo- β -lactamase	AFN85388	CHR	<i>Erythrobacter aquimaris</i>	318	(125)
B3	ECM-1	<i>Erythrobacter citreus</i> Metallo- β -lactamase	WP_122630824	CHR	<i>Erythrobacter citreus</i>	303	(125)
B3	EFM-1	<i>Erythrobacter flavus</i> Metallo- β -lactamase	AFN85384	CHR	<i>Erythrobacter flavus</i>	302	(125)
B3	ELM-1	<i>Erythrobacter longus</i> Metallo- β -lactamase	AFN85386	CHR	<i>Erythrobacter longus</i>	313	(125)
B3	ESP-1	<i>Epilithonimonas</i> sp.	AJP77085	CHR	<i>Epilithonimonas tenax</i>	290	(100)
B3	EVM-1	<i>Erythrobacter vulgaris</i> Metallo- β -lactamase	AFN85385	CHR	<i>Qipengyuania vulgaris</i>	305	(125)
B3	FEZ-1	<i>Fluoribacter gormanii</i> endogenous Zn β -lactamase	CAB96921	CHR	<i>Fluoribacter gormanii</i>	282	(126)
B3	GOB-1	<i>Elizabethkingia meningoseptica</i> class B	AAF04458	CHR	<i>Elizabethkingia meningoseptica</i>	290	(127)
B3	L1	Labile β -lactamase from <i>S. maltophilia</i>	CAA52968	CHR	<i>Stenotrophomonas maltophilia</i>	290	(128)
B3	LMB-1	LinZ Metallo-Beta-lactamase	AMK49163	P	<i>Enterobacter cloacae</i>	304	(129, 130)
B3	LMB-2	LinZ Metallo-Beta-lactamase	SEI10464	CHR	<i>Rheinheimera pacifica</i>	304	–
B3	LRA2-1	Beta-lactam resistance from Alaska	ACH58985	CHR	Uncultured bacterium	302	(131)

B3	LRA3-1	Beta-lactam resistance from <u>A</u> laska	ACH58987	CHR	Uncultured bacterium	302	(131)
B3	LRA7-1	Beta-lactam resistance from <u>A</u> laska	ACH58998	CHR	Uncultured bacterium	302	(131)
B3	LRA8-1	Beta-lactam resistance from <u>A</u> laska	ACH58988	CHR	Uncultured bacterium	305	(131, 132)
B3	LRA12-1	Beta-lactam resistance from <u>A</u> laska	ACH58990	CHR	Uncultured bacterium	293	(131)
B3	LRA17-1	Beta-lactam resistance from <u>A</u> laska	ACH58994	CHR	Uncultured bacterium	294	(131)
B3	LRA19-1	Beta-lactam resistance from <u>A</u> laska	ACH59005	CHR	Uncultured bacterium	300	(131)
B3	MEMA1-1	<u>M</u> eropenem resistance <u>A</u> 1	KY705336*	CHR	Uncultured bacterium	285	(133)
B3	MIM-1	<u>M</u> aynooth <u>I</u> mipenemase-1	AIT78529	CHR	<i>Novosphingobium pentaromativorans</i>	299	(134)
B3	MSI-1	<u>M</u> assilia sp.	AJP77057	CHR	<i>Massilia oculi</i>	341	(100)
B3	NWM-1	<u>N</u> orth <u>R</u> hine- <u>W</u> estphalia <u>M</u> etallo- β -lactamase	QXM27671	CHR	<i>Pseudomonas aeruginosa</i>	310	–
B3	PAM-1	<u>P</u> seudomonas <u>a</u> lcaligenes <u>M</u> etallo- β -lactamase	BAO01151	CHR	<i>Pseudomonas alcaligenes</i>	287	(135)
B3	PAM-2	<u>P</u> seudomonas <u>a</u> lcaligenes <u>M</u> etallo- β -lactamase	BCG24254	CHR	<i>Pseudomonas tohonis</i>	287	(136)
B3	PEDO-1	<u>P</u> edobacter sp.	AJP77059	CHR	<i>Pedobacter roseus</i>	286	(100)
B3	PEDO-2	<u>P</u> edobacter sp.	AJP77071	CHR	<i>Pedobacter borealis</i>	285	(100)
B3	PJM-1	<u>P</u> seudoxanthomonas <u>j</u> aponensis <u>M</u> etallo- β -lactamase	WP_213603971	CHR	<i>Pseudoxanthomonas japonensis</i>	301	(137)
B3	PLN-1	<u>P</u> edobacter <u>l</u> usitanus	KIO75746	CHR	<i>Pedobacter lusitanus</i>	289	(138)
B3	POM-1	<u>P</u> seudomonas <u>o</u> titidis <u>M</u> etallo- β -lactamase	ABY56045	CHR	<i>Pseudomonas otitidis</i>	286	(139)
B3	PNGM-1	<u>P</u> apua <u>N</u> ew <u>G</u> uinea <u>M</u> etallo- β -lactamase	AWN09461	CHR	Uncultured bacterium	386	(140)
B3	RM3-1	Name of clone	AGU01679	CHR	Uncultured bacterium	302	(84, 141)
B3	SAM-1	<u>S</u> imidiua <u>a</u> garivorans <u>M</u> etallo- β -lactamase	AFV00127	CHR	<i>Simidiua agarivorans</i>	295	(134)
B3	SER-1	<u>S</u> almonella <u>e</u> nterica	APY61104	?	<i>Salmonella enterica</i> ser Hillingdon	294	(33)

B3	SIE-1	<u>S</u> phingobium <u>i</u> ndicum B3- <u>E</u>	KEY99315	CHR	<i>Sphingobium indicum</i>	307	(142)
B3	SIQ-1	<u>S</u> phingobium <u>i</u> ndicum B3- <u>Q</u>	SMF77924	CHR	<i>Allosphingosinicella indica</i>	290	(33)
B3	SMB-1	<u>S</u> erratia <u>M</u> etallo- <u>B</u> eta-lactamase	BAL14456	IS	<i>Serratia marcescens</i>	280	(143)
B3	SPG-1	<u>S</u> phingomonas sp.	AJP77080	CHR	<i>Sphingomonas</i> sp.	285	(100)
B3	SPR-1	<u>S</u> erratia <u>p</u> roteamaculans	ABV42357	CHR	<i>Serratia proteamaculans</i>	298	(144)
B3	SSE-1		SBV32245	CHR	Uncultured <i>Sphingopyxis</i> sp.	288	(33)
B3	B3SU1-1	Sub-class B3 and author	QWJ89341	CHR	Uncultured bacterium	303	–
B3	B3SU2-1	Sub-class B3 and author	QWJ89342	CHR	Uncultured bacterium	293	–
B3	THIN-B	<u>J</u> anthinobacterium <u>l</u> ividum class <u>B</u>	CAC33832	CHR	<i>Janthinobacterium lividum</i>	316	(145)

^a The underlined letters form the name of the β -lactamase

^b Chr, Chromosome; In, integron; IS, insertion sequence; P, plasmid; Tn, transposon; –, unknown.

* No GenBank accession available.

Table 2. Synthetic mutants of NDM-1 : bacteriological (MIC) and enzymatic (kinetic constants) changes

Mutation	MIC ^a ($\mu\text{g}\cdot\text{ml}^{-1}$)						K_m (μM) ; k_{cat} (s^{-1}) ; k_{cat}/K_m ($\mu\text{M}^{-1}\cdot\text{s}^{-1}$)						Refer ence
	AMP ^b	FOT ^b	CAZ ^b	FOX _b	IMP ^b	MER ^b	AMP _b	FOT _b	CAZ _b	FOX _b	IMP _b	MER _b	
WT	4096	256			16		143	6			65		(46)
							550	85		238			
							3.84	13.79		3.71			
F64H	4096	256→			16→		188	6		164			(46)
	→						793	83		409			
							4.27	14.80		2.50			
D84E	256↘	16↘			1↘		82	16		70			(46)
							597	113		153			

W87P	2048↘	32↘	2↘	7.29 518 1823 3.53	6.77 6 46 8.50	2.20 295 351 1.20	(46)
K121R	512↘	64↘	4↘	61 26 0.43	4 13 3.69	31 36 1.20	(46)
K121T	512↘	64↘	2↘	231 246 1.06	10 50 5.13	117 50 0.43	(46)
G195A	4096 →	256→	8↘	57 248 4.43	4 32 7.74	52 94 1.84	(46)
D199E	1024↘	64↘	2↘	11 23 2.10	6 48 7.65	6 17 2.81	(46)
K224H	256↘	128↘	0.5↘	906 330 0.36	26 111 4.24	ND ND 0.08	(46)
K224R	2048↘	256→	4↘	179 294 1.65	3 39 12.81	69 62 0.90	(46)
D225E	4096 →	128↘	16→	41 102 2.54	4 38 9.78	50 117 2.37	(46)
G232A	2048↘	64↘	1↘	178 417 2.39	24 90 3.80	ND ND 0.63	(46)
N233H	4096 →	256→	8↘	56 591 10.58	3 55 20.42	134 286 2.22	(46)
N233Q	2048↘	256→	2↘	160 279	1.1 25	565 288	(46)

							1.74	22.95			0.51		
WT	>256	>256	64	32	8	16	94.5	53	99.5	41.3	73.5	53.5	(41)
							471	332	114	23	567	237	
							4.98	6.26	1.15	0.56	7.71	4.43	
W93A	32↘	32↘	16↘	4↘	2↘	2↘	128.9	81.9	121.6	67	98.8	87.9	(41)
							394	286	92	17	439	197	
							3.06	3.49	0.76	0.25	4.44	2.24	
WT	>256					16	193					59	(45)
							139					35	
							0.72					0.59	
Y229W	128↘					8↘	297					268	(45)
							253					435	
							0.85					1.62	
WT		128	>128	8	>64	>64					35	80	(43,
											64	75	44)
											1.83	0.94	
L209F		1↘	16↘	8→	0.25	<0.0625					33	50	(43,
					↘	↘					0.55	0.86	44)
											0.01	0.017	
											7		
Y229W		>128	>128	8→	>64	>64→					81	259	(44)
		→	→	→	→	→					38	820	
											0.47	3.17	
L209F/Y229W		32↘	32↘	4↘	64↘	>64→					120	88	(44)
											55	208	
											0.46	2.36	
V88L/M154L (NDM-5)	>500				>50	>50	117.5				6.32	11.8	(42)
							1912				44	190.7	
							16				7	16.1	
V88L/E152A/M154L	8↘				0.8↘	0.4↘	207.3				39.3	33.2	(42)
							239				94	81.1	
							1.15				2.3	2.4	

^a The arrows represent the variation of CMI compared to WT.

^b AMP : ampicillin ; FOT : cefotaxime ; CAZ : ceftazidime ; FOX : ceftazidime ; IMP : imipenem ; MER: meropenem

Table 3. Synthetic mutants of IMP-1 : bacteriological (MIC) and enzymatic (kinetic constants) changes

Mutation	MIC ^a ($\mu\text{g}\cdot\text{ml}^{-1}$)					K_m (μM) ; k_{cat} (s^{-1}) ; k_{cat}/K_m ($\mu\text{M}^{-1}\cdot\text{s}^{-1}$)						Reference
	AMP ^b	FOT ^b	CAZ ^b	FOX ^b	IMP ^b	MER ^b	AMP ^b	FOT ^b	CAZ ^b	FOX ^b	IMP ^b	
WT	128		256		2	2	300		16.7	27	9	(54)
							46		1.1	3.9	3.7	
							0.15		0.066	0.144	0.41	
S262G/E126G (IMP-3)	8↘		64↘		0.25↘	8↗						(54)
S262G (IMP-6)	8↘		64↘		0.25↘	4↗	300		91	170	6.5	(54)
							4.9		5.9	11.6	10	
							0.016		0.065	0.07	1.54	
V67F (IMP-10)	16↘		>512↗		4↘	8↗	ND		36	92	17	(54)
							ND		7.2	15.2	17.9	
							0.006		0.2	0.17	1.1	
S262G/G235S (IMP-25)	8↘		128↘		0.25↘	8↗						(54)
E59K (IMP-30)	64↘		256→		1↘	1↘						(54)
E126G (IMP-34)	128→		256→		2→	2→						(54)
V67F/F87S (IMP-40)	4↘		256→		4↗	8↗						(54)
G63R (IMP-42)	64↘		512↗		1↘	2→						(54)
L82I/V96G (IMP-52)	128→		256→		1↘	4↗						(54)
E207K (IMP-60)	64↘		128↘		0.5↘	0.5↘						(54)
N129I (IMP-61)	128→		256→		2→	4↗						(54)

V66F (IMP-66)	32↘	128↘	1↘	8↗						(54)
L304I (IMP-70)	128→	256→	2→	1↘						(54)
V67A (IMP-76)	8↘	128↘	0.5↘	8↗						(54)
V67F/L250S (IMP-77)	16↘	>512↗	2→	8↗						(54)
V67F/S262G (IMP-78)	4↘	128↘	0.25↘	32↗	600	132	270	20.2		(54)
					2.3	20.5	20.3	24.8		
					0.004	0.16	0.075	1.23		
K249R (IMP-79)	128→	256→	2→	4↗						(54)
V67F/S262A (IMP-80)	8↘	512↗	1↘	8↗						(54)
L82I	128→	256→	2→	2→						(54)
WT							1.6	19		(56)
							12.7	41		
							8	2.2		
K161R							480	>1000		(56)
							28	>1		
							0.57	0.0013		
K161A							800	>1000		(56)
							9	>7.1		
							0.011	0.0077		
K161E							1100	>1000		(56)
							1.3	>2.8		
							0.003	0.0045		
N167A							33	>1000		(56)
							90	>140		
							2.7	0.34		
N167D							77	>1000		(56)
							38	>100		
							0.5	0.16		
WT	125	250			97	0.98		59		(47)
			3		62	16		98		
					0.64	17		1.7		

N233A	31↘	63↘	0.25↘	110	30	>1000	(47)
				230	495	>970	
				2.1	16	0.97	
N233C	<2↘	<2↘	0.25↘	1098	76	>2000	(47)
				9.1	51	>5.4	
				0.0083	0.67	0.0027	
N233D	250↗	500↗	3→				(47)
N233E	125→	250→	3→	92	8	178	(47)
				416	34	111	
				4.5	4.3	0.62	
N233F	125→	250→	3→				(47)
N233G	125→	500↗	0.38↘				(47)
N233H	125→	125↘	0.5↘				(47)
N233I	16↘	125↘	0.38↘				(47)
N233K	16↘	63↘	0.38↘	1445	98	>2000	(47)
				132	595	>336	
				0.091	6.1	0.17	
N233L	16↘	250→	0.5↘				(47)
N233M	16↘	500↗	0.75↘				(47)
N233P	125→	125↘	0.38↘				(47)
N233Q	125→	500↗	0.2↘				(47)
N233R	31↘	250→	0.38↘	501	73	>2000	(47)
				83	391	>134	
				0.17	5.3	0.067	
N233S	125→	500↗	1.5↘				(47)
N233T	16↘	500↗	0.38↘				(47)
N233V	31↘	500↗	0.38↘				(47)
N233W	250↗	63↘	1.5↘				(47)
N233Y	125→	125↘	3→				(47)

^a The arrows represent the variation of CMI compared to WT.

^b AMP : ampicillin ; FOT : cefotaxime ; CAZ : ceftazidime ; FOX : ceftazidime ; IMP : imipenem ; MER: meropenem


[H2 Secondary and tertiary structure]

The typical three-dimensional structure of class B β -lactamase contains a characteristic $\alpha\beta/\beta\alpha$ motif known as the MBL fold. Structurally, class B β -lactamases belong to the *Lactamase_B* PFAM family (PF00753) and share the same overall fold with many other enzymes that catalyze very different biochemical reactions (27). Indeed, MBLs are part of a larger group of binuclear metallohydrolases that require two closely spaced transition metal ions to carry out a great variety of hydrolytic reactions (146). It was proposed that MBLs present a modular structure in their active sites that can be dissected into two halves: one providing the attacking nucleophile, and the second one stabilizing a negatively charged reaction intermediate (147).

The X-ray structure of the MBL from *Bacillus cereus* BcII (strain 569/H/9) was published in 1995 (148), revealing a new fold. This represents the first structure of a protein from this family (subclass B1). In 1998 was published the first structure of a B3 subclass MBL (L1 from the opportunistic pathogen *Stenotrophomonas maltophilia*) (149) and in 2005 the first structure of a B3 subclass MBL (CphA from *Aeromonas hydrophila*) (150).

The active site is organized around one (subclass B2) or two (subclasses B1 and B3) zinc ions that coordinate six very conserved residues specific for each subclass (Figure 3.2.3). These zinc ions are essential for the enzymatic activity and play key roles in the catalytic mechanism, including facilitating nucleophilic attack on the amide carbonyl by the zinc-bound hydroxide ion, stabilizing the anionic tetrahedral intermediate and coordinating the departing amine nitrogen (151). In some cases, steric constraints imposed by the N-terminus may limit the affinity of the active site for β -lactams (33, 141).

Quantum mechanical and molecular dynamics simulations provided insight into the conformational flexibility of these enzymes, the mechanism for carbapenem hydrolysis and the binding mode of different MBL substrates and inhibitors (152-154).




*** Insert Figure 3.2.3 ***

Caption: Active site residues coordinating the zinc ions in representative members of subclass B1 (a, BcII, orange), B2 (b, CphA, cyan) and B3 (c, L1, pink) MBLs. The zinc ions and the bridged water molecules are represented as gray and red spheres, respectively. The residues are numbered according to the BBL standard numbering scheme (35, 36).

Credit: The authors (Elsa Denakpo, Guillaume Arlet, Alain Philippon, Bogdan I. Iorga)

The number of MBL structures deposited in the Protein Data Bank (PDB) has increased significantly during the recent years, especially for the subclass B1 (Figure 3.2.4). This increase is likely due to the importance of structural studies to guide and accompany the synthetic efforts focused on the development of efficient inhibitors targeting clinically-relevant MBLs (e.g. NDM-1, VIM-1, IMP-1, all belonging to subclass B1).



*** Insert Figure 3.2.4 ***

Caption: Evolution of the number of MBL structures deposited in the Protein Data Bank (PDB) over the years. Data was extracted from the Beta-Lactamase DataBase (<http://bldb.eu/BLDB/S-BLDB.php>).

Credit: The authors (Elsa Denakpo, Guillaume Arlet, Alain Philippon, Bogdan I. Iorga)

[H1 Physiologic and pathologic role of metallo- β -lactamases]

[H2 Metallo- β -lactamases in clinical microbiology]

The emergence of these enzymes in human infections is the consequence of the use of carbapenems in therapy. Indeed, MBLs are able to hydrolyze all β -lactams except monobactams such as aztreonam. The transferable carbapenemases that currently predominate are KPCs (class A), OXA-48-like (class D) and MBLs (class B). Among these

MBLs, the most important ones belong to subclass B1, IMP (Imipenemase), VIM (Verona integron-encoded metallo- β -lactamase) and NDM (New Delhi metallo- β -lactamase) (155). IMP-1 was described in the 90s in Japan in *Pseudomonas aeruginosa* and *Serratia marcescens* and currently has more than 90 variants (<http://bldb.eu/BLDB.php?prot=B1#IMP>) (26, 40). The first VIM-like enzyme was described in Italy in 1997 in *P. aeruginosa* and more than 80 variants are currently reported (<http://bldb.eu/BLDB.php?prot=B1#VIM>) (26, 40). NDM-1 was identified in Sweden in 2008 (patient returning from India) in *Klebsiella pneumoniae* and more than 45 variants were characterized to date (<http://bldb.eu/BLDB.php?prot=B1#NDM>) (26, 40).

The IMP and VIM enzymes are encoded by gene cassettes in integrons which are usually integrated into transposons (156). The *bla*_{NDM} genes are carried by composite transposons like *Tn125* bordered by insertion sequences, in particular *ISAba125*, but multiple recombinations were subsequently observed (25).

While these enzymes have been described all over the world, it seems that IMP- and VIM-type enzymes are predominant in some specific countries: IMP in Japan, Australia and Thailand, and VIM in Greece, Italy and neighboring countries (26, 155).

NDM-like enzymes are endemic in India and Pakistan and neighboring countries. Since 2010, we assist to a worldwide dissemination of NDM-1 (24-26). These genes are carried by a wide variety of plasmids (both narrow and broad spectrum), and in particular from the IncX3 group (24, 25). On these plasmids, NDM enzymes are often associated with resistances to other families of antibiotics (aminoglycosides, fluoroquinolones) (24). The hosts harboring these plasmids are both Enterobacterales and particularly *E. coli* and *K.*

pneumoniae, as well as *P. aeruginosa* and *Acinetobacter baumannii*. In addition, NDM enzymes have been also reported in animals and in the environment (157).

[H2 Metallo- β -lactamases in veterinary medicine and environment]

Considering the animal ecosystem and the enzymatic carbapenem resistance (ECR) mediated by MBLs, numerous publications showed the implication of several transferable types such as IMP-1, NDM-5, VIM-1 and even SIM-1 produced by Enterobacterales (mainly *Escherichia coli*, *K. pneumoniae*, and *Salmonella enterica*), but also by *P. aeruginosa* and *Acinetobacter* spp. (158-165). Various animal species were implicated such as chickens, pigs, calves, boars, flies, birds and particularly animal companion (dogs, cats). Such enzymatic resistance is widespread in countries such as in Algeria, Australia, Brazil, China, Egypt, India, Japan, USA and in Europe. Considering that carbapenems are not authorized in veterinary medicine, such results indicate the importance of a rational use of antibiotics in this field and their prohibition as growth promoters. Nevertheless, the impact of animal reservoirs on human health still remains unclear and debatable; there are several examples of direct links suggesting a potential transmission way of the ECR plasmids between humans and companion animals (158, 166).

A wide range of Gram-negative bacteria issued from nonclinical samples, distributed in various ecosystems such as soil, sediments, sewage, tap water, river, sea water or coastal mud, are able to naturally produce various MBLs (see Table 1 for representative examples). The phylum Bacteroidota (formerly Bacteroidetes) is composed of several classes of bacteria that can be opportunistic pathogens, including the following genera: *Bacteroides*, *Chitinophaga*, *Chryseobacterium*, *Echinicola*, *Elisabethkingia*, *Empedobacter*,

Epilithonimonas, *Fibrella*, *Flavobacterium*, *Myroides*, *Myxococcus*, *Ornithobacterium*, *Pedobacter*, *Pontibacter*, *Sphingobacterium*, and *Zobellia*. Nevertheless, other MBL-producing Proteobacteria are also mentioned in Table 1, such as *Chromobacterium*, *Erythrobacter*, *Hirschia*, *Pseudobacteriovora*, *Shewanella*, *Sediminispirochaeta*, *Stigmatella*, and *Teredinibacter*. Well-known transferable carbapenem resistance genes (IMP-, NDM- and VIM-types) have been previously reported to spread rapidly to humans via pathogen bacteria such as Enterobacterales, *P. aeruginosa* and *Acinetobacter* spp. (167-171). Such resistance genes encoding MBLs were mainly located on mobile genetic elements (plasmids, transposons, integrons, insertion sequences), which likely contribute to their rapid spread to different bacteria. Such global dissemination of carbapenem-resistant potential opportunistic bacteria is now recognized as a worldwide threat to public health, particularly from a One Health perspective, and a continuous monitoring of some environments is required (172, 173).

[H2 Treatment options for infections mediated by metallo- β -lactamases]

The treatment options for MBLs-producers and in particular for bacteria producing NDM are very limited. For serious infections, combination therapy including a polymyxin is the preferred option. However, resistance to polymyxins is emerging (174). Although the introduction of new antibiotics allows the treatment of certain strains of carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant *P. aeruginosa* (CRPA) with polymyxin-sparing regimens, the use of polymyxins is currently still necessary in carbapenem-resistant *A. baumannii* (CRAB), and in CRE and CRPA harboring MBLs

(175). The activity of β -lactam antibiotics against MBL-producing Enterobacterales in animal infection models was recently reviewed (176).

Alternatively, cefiderocol is a siderophore cephalosporin antibiotic with potent activity against carbapenem-resistant Gram-negative bacteria, including both serine- and metallo-carbapenemase positive strains (177, 178). Cefiderocol is the only of the four new agents with efficacy against MBLs and resistant *Acinetobacter* species, but comparator studies using best available therapy for carbapenem-resistant Gram-negative bacterial infections show higher mortality rates with this new drug, making its role in clinical therapy still to be determined (179).

With the exception of taniborbactam (VNRX-5133) and xeruborbactam (QPX7728), none of the novel β -lactam- β -lactamase inhibitor combinations (avibactam, nacubactam, taniborbactam, zidebactam) present *in vitro* activity against Enterobacterales or *P. aeruginosa* producing MBLs or against carbapenemase-producing *A. baumannii* (180). However, aztreonam can be used in combination with these inhibitors against multidrug resistant (MDR) Enterobacterales and *P. aeruginosa* producing MBLs (181). The aztreonam/avibactam combination is efficient against MBL-producing enteric bacteria owing to the stability of the monobactam to these enzymes, but resistance is still an issue for MBL-producing non-fermentative bacteria (182).

[H1 Classes of metallo- β -lactamase inhibitors and their design]

For many years, the design of a clinically-useful MBL inhibitors was an elusive task (183). Many excellent reviews included a comprehensive description of these studies, on β -lactamase inhibitors in general (184-188) or more specifically on MBL inhibitors (189-

206). A detailed description of these studies is outside the scope of this chapter, and only a few representative examples will be detailed below.

[H2 Metallo- β -lactamase specific inhibitors]

In an early study, Kurosaki *et al.* have exploited the common features of substrate and inhibitor binding to MBLs to generate a new class of irreversible thiol inhibitor (e.g. 3-(3-mercaptopropionylsulfanyl)propionic acid pentafluorophenyl ester) (207, 208).

Bisthiazolidines (BTZs) were designed as substrate-mimicking scaffolds for the inhibition of the NDM-1 carbapenemase. Inspired by known interactions of MBLs with β -lactams, these compounds share some features with the β -lactam substrates, which can be modified with metal-binding groups to target the MBL active site (209-212). Further studies showed that 2-mercaptomethyl thiazolidines (MMTZs) inhibit all MBL subclasses (B1, B2, B3) by maintaining a conserved binding mode (213, 214).

Another MBL inhibitor, ANT431, was shown to potentiate the activity of meropenem against a broad range of MBL-producing CRE and restore its efficacy against an *Escherichia coli* NDM-1-producing strain in a murine thigh infection model (215, 216).

An optimized derivative, ANT2681, is a specific, competitive inhibitor of MBLs with potent activity against NDM enzymes. Susceptibility studies evidenced the efficacy of ANT2681 in combination with meropenem against MBL-positive Enterobacterales (including NDM-CRE) (217, 218).

Some of the novel inhibitory approaches involve the use of chelating agents or metal-based drugs that displace the native metal ion (219). For example, a fungal natural product, aspergillomarasmine A (AMA), was identified as a rapid and potent inhibitor of two

clinically relevant MBLs, NDM-1 and VIM-2. AMA also fully restored the activity of meropenem against Enterobacterales, *Acinetobacter* spp. and *Pseudomonas* spp. possessing either VIM or NDM-type alleles (220-222). Mechanistic studies showed that AMA inhibits the MBLs by removal of the active site metal ions required for β -lactam hydrolysis (223, 224). Significant improvements were obtained through the total synthesis (225-229), solid-phase synthesis (230), chemoenzymatic synthesis (231) and fragment-based drug discovery (FBDD) (232) of AMA and its derivatives.

A series of 1,2,4-triazole-3-thione compounds was designed and synthesized as inhibitors of dizinc MBLs (233-239). Computational studies revealed the intermolecular interactions of these compounds with the extended recognition site of VIM-2 (240). Some compounds showed submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition and the mechanism of this inhibition involved at least partially the stripping of the catalytic zinc ions. A strong synergistic activity with meropenem was observed (16- to 1000-fold minimum inhibitory concentration (MIC) reduction) against VIM-type- and NDM-1-producing ultrasensitive clinical isolates, including Enterobacterales and *P. aeruginosa*, indicating an efficient penetration of the bacterial cells. Furthermore, selected compounds exhibited no or moderate toxicity toward HeLa cells, favorable absorption, distribution, metabolism, excretion (ADME) properties, and no or modest inhibition of several mammalian metalloenzymes (241).

[H2 Covalent metallo- β -lactamase inhibitors]

A recent review summarizes the current knowledge on the covalent inhibitors of MBLs and their inhibition modes, highlighting the importance of the rational design of covalent

MBL inhibitors and the development of dual-action covalent MBL/SBL inhibitors based on lysine residue of MBLs and serine residue of SBLs (242).

Compounds from the ebsulfur family were reported to inhibit NDM-1 with IC_{50} values ranging from 0.16 to 9 μ M. Labelling of NDM-1 using a constructed fluorescent ebsulfur derivative (Ebs-R) suggested that the inhibitor is covalently bound to the target. Moreover, labelling NDM-1 in living *E. coli* cells with Ebs-R by confocal microscopic imaging showed the real-time distribution of the intracellular recombinant protein (243, 244).

The *O*-aryloxycarbonyl hydroxamates are known inactivators of *Enterobacter cloacae* P99 class C SBL with an unusual covalent mechanism targeting both active-site Ser and Lys residues. Unexpectedly, a recent study evidenced that these compounds can also serve as a classical affinity label for NDM-1. Mass spectrometry and ultraviolet photodissociation for extensive fragmentation show a stoichiometric covalent labeling that occurs specifically at Lys211. Moreover, the X-ray crystal structure of the inactivated enzyme reveals that the covalent adduct is bound at the substrate-binding site but not directly coordinated to the active-site zinc cluster (244, 245).

Additional studies also reported 3-bromopyruvate (246), 1,2-isoselenazol-3(2*H*)-one derivatives (247) and disulfiram (248) as potent covalent NDM-1 inhibitors.

[H2 Conjugate metallo- β -lactamase inhibitors]

Cephalosporin prodrugs containing several MBL inhibitors (thiomandelic acid, dipicolinic acid, 8-thioquinoline) were designed and synthesized for the delivery of the active compounds in a spatiotemporally controlled fashion. These conjugates demonstrated potent inhibition of NDM, VIM, and IMP classes of MBLs and displayed potent synergy

with meropenem against MBL-expressing clinical isolates of *K. pneumoniae* and *E. coli* (249, 250). Kinetic experiments showed that thiomandelic acid acts as a slowly turned-over substrate (249).

Similarly, a cephalosporin-tripodalamine conjugate (DPASC) was shown to inhibit different MBLs with high efficacy and low toxicity. The cephalosporin tag blocks the ligand binding site to reduce toxicity and is cleaved by MBLs to release active ligands to inhibit MBLs *in situ* (251).

[H2 Dual serine/metallo- β -lactamase inhibitors]

A recent review describes the current knowledge about the dual SBL/MBL inhibitors, including their modes of inhibition and the crystal structures when available (252).

A series of azetidinimines, imino-analogues of β -lactams, was reported as efficient non-covalent inhibitors of all four classes (A, B, C, D) of β -lactamases. Despite the structural and mechanistic differences between the clinically-relevant carbapenemases KPC-2 and OXA-48 SBLs and NDM-1 MBL, all three enzymes were inhibited with K_i values below 0.3 μ M, while the class C cephalosporinase CMY-2 showed 86% inhibition at 10 μ M. Selected azetidinimines were also able repotentiate imipenem against a resistant strain of *E. coli* expressing NDM-1 (253).

Similarly, compounds derived from the benzo-[b]-thiophene-2-boronic acid (BZB) and 4-amino-1,2,4-triazole-3-thione scaffolds showed cross-class micromolar inhibition against class A SBL KPC-2 and class B1 MBLs VIM-1 and IMP-1 (254, 255).

The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of β -lactamase inhibitor in clinical development combined with cefepime, for the treatment of infections caused by

β -lactamase-producing CRE and CRPA. VNRX-5133 inhibits SBLs and some clinically important MBLs, including NDM-1, VIM-1 and VIM-2. However, VNRX-5133's activity against IMP-1, and against other B2 and B3 MBLs tested, was lower or not observed. Inhibition is achieved by mimicking the transition state structure and exploiting interactions with highly conserved active-site residues, while employing distinct mechanisms to inhibit both SBLs and MBLs. It is a reversible covalent inhibitor of SBLs with slow dissociation and a prolonged active-site residence time, while in MBLs it behaves as a competitive inhibitor (256-258).

Xeruborbactam (QPX7728) is an ultra-broad-spectrum β -lactamase inhibitor that is currently in clinical development. In addition to potent inhibition of clinically important SBLs it also inhibits many MBLs. This compound displays a remarkably broad spectrum of inhibition, including class B and class D enzymes, and is little affected by porin modifications and efflux. QPX7728 combinations with several β -lactam antibiotics shows broad coverage of Enterobacterales, *A. baumannii* and *P. aeruginosa*. An important aspect is that QPX7728 can also be delivered orally (259-268).

[H1 Metallo- β -lactamase inhibitors in clinical development]

Currently, the most advanced clinical trial targeting MBL-producing bacteria involves the combination cefepime/VNRX-5133 (taniborbactam), which has completed the phase 3 with the sponsorship of Venatorx Pharmaceuticals (code: NCT03840148). The combination aztreonam/avibactam is tested in phase 3 since December 2020 with the sponsorship of Pfizer (code: NCT03580044). Finally, the combination QPX2014/QPX7728 (xeruborbactam) has completed the phase 1 with the sponsorship of

Qpex Biopharma (codes: NCT04380207 and NCT05072444). This information was last updated in January 2023.

[H1 Conclusion]

The emergence of MBL-producing organisms has become a significant public health concern due to their ability to cause multidrug-resistant infections. While there are compounds that have been identified as MBL inhibitors, none are currently clinically-approved. However, several compounds are being evaluated in clinical trials and may be approved in the near future.

[H1 Acknowledgments]

This work was supported, in part, by grants from the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT, ANR-10-LABX-33), the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR, ANR-14-JAMR-0002), and the PPR Antibioresistance (ANR-20-PAMR-0010).

[H1 References]

1. Ambler RP. The structure of β -lactamases. *Philos Trans R Soc Lond B Biol Sci.* 1980;289(1036):321-31.
2. Bush K. The ABCD's of β -lactamase nomenclature. *J Infect Chemother.* 2013;19(4):549-59.

3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother.* 1995;39(6):1211-33.
4. Bush K. Past and present perspectives on β -lactamases. *Antimicrob Agents Chemother.* 2018;62(10):e01076-18.
5. Philippon A, Dusart J, Joris B, Frère JM. The diversity, structure and regulation of β -lactamases. *Cell Mol Life Sci.* 1998;54(4):341-6.
6. Helfand MS, Bonomo RA. β -Lactamases: a survey of protein diversity. *Curr Drug Targets Infect Disord.* 2003;3(1):9-23.
7. Queenan AM, Bush K. Carbapenemases: the versatile β -lactamases. *Clin Microbiol Rev.* 2007;20(3):440-58.
8. Bush K. Bench-to-bedside review: The role of β -lactamases in antibiotic-resistant Gram-negative infections. *Crit Care.* 2010;14(3):224.
9. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β -lactamases from gram-negative bacteria. *Annu Rev Microbiol.* 2011;65:455-78.
10. Bush K. Proliferation and significance of clinically relevant β -lactamases. *Ann N Y Acad Sci.* 2013;1277:84-90.
11. Frère JM, Sauvage E, Kerff F. From "an enzyme able to destroy penicillin" to carbapenemases: 70 years of β -lactamase misbehaviour. *Curr Drug Targets.* 2016;17(9):974-82.
12. Bush K. Metallo- β -lactamases: a class apart. *Clin Infect Dis.* 1998;27 Suppl 1:S48-53.

13. Cricco JA, Vila AJ. Class B β -lactamases: the importance of being metallic. *Curr Pharm Des.* 1999;5(11):915-27.
14. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo- β -lactamases: the quiet before the storm? *Clin Microbiol Rev.* 2005;18(2):306-25.
15. Walsh TR. The emergence and implications of metallo- β -lactamases in Gram-negative bacteria. *Clin Microbiol Infect.* 2005;11 Suppl 6:2-9.
16. Crowder MW, Spencer J, Vila AJ. Metallo- β -lactamases: novel weaponry for antibiotic resistance in bacteria. *Acc Chem Res.* 2006;39(10):721-8.
17. Bebrone C. Metallo- β -lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. *Biochem Pharmacol.* 2007;74(12):1686-701.
18. Cornaglia G, Akova M, Amicosante G, Cantón R, Cauda R, Docquier JD, Edelstein M, Frère JM, Fuzi M, Galleni M, Giamarellou H, Gniadkowski M, Koncan R, Libisch B, Luzzaro F, Miriagou V, Navarro F, Nordmann P, Pagani L, Peixe L, Poirel L, Souli M, Tacconelli E, Vatopoulos A, Rossolini GM. Metallo- β -lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. *Int J Antimicrob Agents.* 2007;29(4):380-8.
19. Cornaglia G, Giamarellou H, Rossolini GM. Metallo- β -lactamases: a last frontier for β -lactams? *Lancet Infect Dis.* 2011;11(5):381-93.
20. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. *Trends Microbiol.* 2011;19(12):588-95.
21. Palzkill T. Metallo- β -lactamase structure and function. *Ann N Y Acad Sci.* 2013;1277:91-104.

22. Mojica MF, Bonomo RA, Fast W. B1-Metallo- β -Lactamases: Where Do We Stand? *Curr Drug Targets*. 2016;17(9):1029-50.
23. Groundwater PW, Xu S, Lai F, Váradi L, Tan J, Perry JD, Hibbs DE. New Delhi metallo- β -lactamase-1: structure, inhibitors and detection of producers. *Future Med Chem*. 2016;8(9):993-1012.
24. Khan AU, Maryam L, Zarrilli R. Structure, genetics and worldwide spread of New Delhi Metallo- β -lactamase (NDM): a threat to public health. *BMC Microbiol*. 2017;17(1):101.
25. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM metallo- β -lactamases and their bacterial producers in health care settings. *Clin Microbiol Rev*. 2019;32(2):e00115-18.
26. Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo- β -lactamases: Structure, function, epidemiology, treatment options, and the development pipeline. *Antimicrob Agents Chemother*. 2020;64(10):e00397-20.
27. Bahr G, González LJ, Vila AJ. Metallo- β -lactamases in the age of multidrug resistance: From structure and mechanism to evolution, dissemination, and inhibitor design. *Chem Rev*. 2021;121(13):7957-8094.
28. Hall BG, Salipante SJ, Barlow M. The metallo- β -lactamases fall into two distinct phylogenetic groups. *J Mol Evol*. 2003;57(3):249-54.
29. Hall BG, Salipante SJ, Barlow M. Independent origins of subgroup B1 + B2 and subgroup B3 metallo- β -lactamases. *J Mol Evol*. 2004;59(1):133-41.

30. López C, Delmonti J, Bonomo RA, Vila AJ. Deciphering the evolution of metallo- β -lactamases: A journey from the test tube to the bacterial periplasm. *J Biol Chem.* 2022;298(3):101665.
31. González JM. Visualizing the superfamily of metallo- β -lactamases through sequence similarity network neighborhood connectivity analysis. *Heliyon.* 2021;7(1):e05867.
32. Galtier N, Gouy M, Gautier C. SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and molecular phylogeny. *Comput Appl Biosci.* 1996;12(6):543-8.
33. Pedroso MM, Waite DW, Melse O, Wilson L, Mitić N, McGeary RP, Antes I, Guddat LW, Hugenholtz P, Schenk G. Broad spectrum antibiotic-degrading metallo- β -lactamases are phylogenetically diverse. *Protein Cell.* 2020;11(8):613-7.
34. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. *Genome Res.* 2004;14(6):1188-90.
35. Galleni M, Lamotte-Brasseur J, Rossolini GM, Spencer J, Dideberg O, Frère JM. Standard numbering scheme for class B β -lactamases. *Antimicrob Agents Chemother.* 2001;45(3):660-3.
36. Garau G, García-Sáez I, Bebrone C, Anne C, Mercuri P, Galleni M, Frère JM, Dideberg O. Update of the standard numbering scheme for class B β -lactamases. *Antimicrob Agents Chemother.* 2004;48(7):2347-9.
37. Philippon A, Labia R, Jacoby G. Extended-spectrum β -lactamases. *Antimicrob Agents Chemother.* 1989;33(8):1131-6.

38. Matagne A, Lamotte-Brasseur J, Frère JM. Catalytic properties of class A β -lactamases: efficiency and diversity. *Biochem J.* 1998;330 (Pt 2)(Pt 2):581-98.
39. Chaïbi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM β -lactamases: phenotypic, genetic and biochemical characteristics. *J Antimicrob Chemother.* 1999;43(4):447-58.
40. Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P, Iorga BI. Beta-lactamase database (BLDB) - structure and function. *J Enzyme Inhib Med Chem.* 2017;32(1):917-9.
41. Khan AU, Rehman MT. Role of non-active-site residue Trp-93 in the function and stability of New Delhi Metallo- β -Lactamase 1. *Antimicrob Agents Chemother.* 2016;60(1):356-60.
42. Kumar G, Issa B, Kar D, Biswal S, Ghosh AS. E152A substitution drastically affects NDM-5 activity. *FEMS Microbiol Lett.* 2017;364(3):fnx008.
43. Marcoccia F, Leiros HS, Aschi M, Amicosante G, Perilli M. Exploring the role of L209 residue in the active site of NDM-1 metallo- β -lactamase. *PLoS One.* 2018;13(1):e0189686.
44. Piccirilli A, Brisdelli F, Aschi M, Celenza G, Amicosante G, Perilli M. Kinetic profile and molecular dynamic studies show that Y229W substitution in an NDM-1/L209F variant restores the hydrolytic activity of the enzyme toward penicillins, cephalosporins, and carbapenems. *Antimicrob Agents Chemother.* 2019;63(4):e02270-18.
45. Chen J, Chen H, Shi Y, Hu F, Lao X, Gao X, Zheng H, Yao W. Probing the effect of the non-active-site mutation Y229W in New Delhi metallo- β -lactamase-1 by site-

directed mutagenesis, kinetic studies, and molecular dynamics simulations. PLoS One. 2013;8(12):e82080.

46. Sun Z, Hu L, Sankaran B, Prasad BVV, Palzkill T. Differential active site requirements for NDM-1 β -lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics. Nat Commun. 2018;9(1):4524.

47. Brown NG, Horton LB, Huang W, Vongpunsawad S, Palzkill T. Analysis of the functional contributions of Asn233 in metallo- β -lactamase IMP-1. Antimicrob Agents Chemother. 2011;55(12):5696-702.

48. Hall BG. *In vitro* evolution predicts that the IMP-1 metallo- β -lactamase does not have the potential to evolve increased activity against imipenem. Antimicrob Agents Chemother. 2004;48(3):1032-3.

49. Liu EM, Pegg KM, Oelschlaeger P. The sequence-activity relationship between metallo- β -lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure. Antimicrob Agents Chemother. 2012;56(12):6403-6.

50. Oelschlaeger P, Mayo SL, Pleiss J. Impact of remote mutations on metallo- β -lactamase substrate specificity: implications for the evolution of antibiotic resistance. Protein Sci. 2005;14(3):765-74.

51. Pegg KM, Liu EM, George AC, LaCuran AE, Bethel CR, Bonomo RA, Oelschlaeger P. Understanding the determinants of substrate specificity in IMP family metallo- β -lactamases: the importance of residue 262. Protein Sci. 2014;23(10):1451-60.

52. Zhang CJ, Faheem M, Dang P, Morris MN, Kumar P, Oelschlaeger P. Mutation S115T in IMP-type metallo- β -lactamases compensates for decreased expression levels caused by mutation S119G. Biomolecules. 2019;9(11):724.

53. Yamaguchi Y, Kuroki T, Yasuzawa H, Higashi T, Jin W, Kawanami A, Yamagata Y, Arakawa Y, Goto M, Kurosaki H. Probing the role of Asp-120(81) of metallo- β -lactamase (IMP-1) by site-directed mutagenesis, kinetic studies, and X-ray crystallography. *J Biol Chem.* 2005;280(21):20824-32.
54. Cheng Z, Bethel CR, Thomas PW, Shurina BA, Alao JP, Thomas CA, Yang K, Marshall SH, Zhang H, Sturgill AM, Kravats AN, Page RC, Fast W, Bonomo RA, Crowder MW. Carbapenem use is driving the evolution of imipenemase 1 variants. *Antimicrob Agents Chemother.* 2021;65(4):e01714-20.
55. Haruta S, Yamaguchi H, Yamamoto ET, Eriguchi Y, Nukaga M, O'Hara K, Sawai T. Functional analysis of the active site of a metallo- β -lactamase proliferating in Japan. *Antimicrob Agents Chemother.* 2000;44(9):2304-9.
56. Haruta S, Yamamoto ET, Eriguchi Y, Sawai T. Characterization of the active-site residues asparagine 167 and lysine 161 of the IMP-1 metallo β -lactamase. *FEMS Microbiol Lett.* 2001;197(1):85-9.
57. Martínez-García L, González-Alba JM, Baquero F, Cantón R, Galán JC. Ceftazidime is the key diversification and selection driver of VIM-type carbapenemases. *mBio.* 2018;9(3):e02109-17.
58. Cheng Z, Shurina BA, Bethel CR, Thomas PW, Marshall SH, Thomas CA, Yang K, Kimble RL, Montgomery JS, Orischak MG, Miller CM, Tennenbaum JL, Nix JC, Tierney DL, Fast W, Bonomo RA, Page RC, Crowder MW. A single salt bridge in VIM-20 increases protein stability and antibiotic resistance under low-zinc conditions. *mBio.* 2019;10(6):e02412-19.

59. Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frère JM, Rossolini GM, Docquier JD. Mutational analysis of VIM-2 reveals an essential determinant for metallo- β -lactamase stability and folding. *Antimicrob Agents Chemother.* 2010;54(8):3197-204.
60. Chen JZ, Fowler DM, Tokuriki N. Comprehensive exploration of the translocation, stability and substrate recognition requirements in VIM-2 lactamase. *Elife.* 2020;9:e56707.
61. Samuelsen Ø, Castanheira M, Walsh TR, Spencer J. Kinetic characterization of VIM-7, a divergent member of the VIM metallo- β -lactamase family. *Antimicrob Agents Chemother.* 2008;52(8):2905-8.
62. Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ. Biochemical characterization of metallo- β -lactamase VIM-11 from a *Pseudomonas aeruginosa* clinical strain. *Antimicrob Agents Chemother.* 2008;52(6):2250-2.
63. Liu Z, Zhang R, Li W, Yang L, Liu D, Wang S, Shen J, Wang Y. Amino acid changes at the VIM-48 C-terminus result in increased carbapenem resistance, enzyme activity and protein stability. *J Antimicrob Chemother.* 2019;74(4):885-93.
64. Merino M, Pérez-Llarena FJ, Kerff F, Poza M, Mallo S, Rumbo-Feal S, Beceiro A, Juan C, Oliver A, Bou G. Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo- β -lactamases. *J Antimicrob Chemother.* 2010;65(9):1950-4.
65. Lassaux P, Traoré DA, Loisel E, Favier A, Docquier JD, Sohier JS, Laurent C, Bebrone C, Frère JM, Ferrer JL, Galleni M. Biochemical and structural characterization of the subclass B1 metallo- β -lactamase VIM-4. *Antimicrob Agents Chemother.* 2011;55(3):1248-55.

66. Rodriguez-Martinez JM, Nordmann P, Fortineau N, Poirel L. VIM-19, a metallo- β -lactamase with increased carbapenemase activity from *Escherichia coli* and *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2010;54(1):471-6.
67. Ikonomidis A, Ntokou E, Maniatis AN, Tsakris A, Pournaras S. Hidden VIM-1 metallo- β -lactamase phenotypes among *Acinetobacter baumannii* clinical isolates. *J Clin Microbiol*. 2008;46(1):346-9.
68. Falcone M, Mezzatesta ML, Perilli M, Forcella C, Giordano A, Cafiso V, Amicosante G, Stefani S, Venditti M. Infections with VIM-1 metallo- β -lactamase-producing *Enterobacter cloacae* and their correlation with clinical outcome. *J Clin Microbiol*. 2009;47(11):3514-9.
69. Zhao WH, Chen G, Ito R, Hu ZQ. Relevance of resistance levels to carbapenems and integron-borne *bla*_{IMP-1}, *bla*_{IMP-7}, *bla*_{IMP-10} and *bla*_{VIM-2} in clinical isolates of *Pseudomonas aeruginosa*. *J Med Microbiol*. 2009;58(Pt 8):1080-5.
70. Hu Z, Zhao WH. Identification of plasmid- and integron-borne *bla*_{IMP-1} and *bla*_{IMP-10} in clinical isolates of *Serratia marcescens*. *J Med Microbiol*. 2009;58(Pt 2):217-21.
71. Singh T, Singh PK, Das S, Wani S, Jawed A, Dar SA. Transcriptome analysis of β -lactamase genes in diarrheagenic *Escherichia coli*. *Sci Rep*. 2019;9(1):3626.
72. Cheung CHP, Alorabi M, Hamilton F, Takebayashi Y, Mounsey O, Heesom KJ, Williams PB, Williams OM, Albur M, MacGowan AP, Avison MB. Trade-offs between antibacterial resistance and fitness cost in the production of metallo- β -lactamases by enteric bacteria manifest as sporadic emergence of carbapenem resistance in a clinical setting. *Antimicrob Agents Chemother*. 2021;65(8):e0241220.

73. Li Y, Zhang R, Wang S. A natural novel mutation in the *bla*_{NDM-5} promoter reducing carbapenems resistance in a clinical *Escherichia coli* strain. *Microbiol Spectr*. 2022;10(1):e0118321.
74. Lin X, Lu J, Qian C, Lin H, Li Q, Zhang X, Liu H, Sun Z, Zhou D, Lu W, Zhu M, Zhang H, Xu T, Li K, Bao Q, Lin L. Molecular and functional characterization of a novel plasmid-borne *bla*_{NDM}-like gene, *bla*_{AFM-1}, in a clinical strain of *Aeromonas hydrophila*. *Infect Drug Resist*. 2021;14:1613-22.
75. Berglund F, Marathe NP, Österlund T, Bengtsson-Palme J, Kotsakis S, Flach CF, Larsson DGJ, Kristiansson E. Identification of 76 novel B1 metallo- β -lactamases through large-scale screening of genomic and metagenomic data. *Microbiome*. 2017;5(1):134.
76. Hussain M, Carlino A, Madonna MJ, Lampen JO. Cloning and sequencing of the metallothioprotein β -lactamase II gene of *Bacillus cereus* 569/H in *Escherichia coli*. *J Bacteriol*. 1985;164(1):223-9.
77. Rossolini GM, Franceschini N, Riccio ML, Mercuri PS, Perilli M, Galleni M, Frère JM, Amicosante G. Characterization and sequence of the *Chryseobacterium (Flavobacterium) meningosepticum* carbapenemase: a new molecular class B β -lactamase showing a broad substrate profile. *Biochem J*. 1998;332(Pt 1):145-52.
78. Boyd DA, Lisboa LF, Rennie R, Zhanel GG, Dingle TC, Mulvey MR. Identification of a novel metallo- β -lactamase, CAM-1, in clinical *Pseudomonas aeruginosa* isolates from Canada. *J Antimicrob Chemother*. 2019;74(6):1563-7.
79. Álvarez-Marín MT, Zarzuela L, Camacho EM, Santero E, Flores A. Detection by metagenomic functional analysis and improvement by experimental evolution of β -lactams resistance genes present in oil contaminated soils. *Sci Rep*. 2022;12(1):10059.

80. Thompson JS, Malamy MH. Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from *Bacteroides fragilis* TAL2480 reveals strong similarity between CfiA and *Bacillus cereus* β -lactamase II. *J Bacteriol.* 1990;172(5):2584-93.
81. Rasmussen BA, Gluzman Y, Tally FP. Cloning and sequencing of the class B β -lactamase gene (ccrA) from *Bacteroides fragilis* TAL3636. *Antimicrob Agents Chemother.* 1990;34(8):1590-2.
82. Bellais S, Naas T, Nordmann P. Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing β -lactamase from *Chryseobacterium gleum*. *Antimicrob Agents Chemother.* 2002;46(9):2791-6.
83. Sóki J, Lang U, Schumacher U, Nagy I, Berényi Á, Fehér T, Burián K, Nagy E. A novel *Bacteroides* metallo- β -lactamase (MBL) and its gene (crxA) in *Bacteroides xylanisolvens* revealed by genomic sequencing and functional analysis. *J Antimicrob Chemother.* 2022;77(6):1553-6.
84. Zhang L, Calvo-Bado L, Murray AK, Amos GCA, Hawkey PM, Wellington EM, Gaze WH. Novel clinically relevant antibiotic resistance genes associated with sewage sludge and industrial waste streams revealed by functional metagenomic screening. *Environ Int.* 2019;132:105120.
85. Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P. Characterization of DIM-1, an integron-encoded metallo- β -lactamase from a *Pseudomonas stutzeri* clinical isolate in the Netherlands. *Antimicrob Agents Chemother.* 2010;54(6):2420-4.

86. Bellais S, Girlich D, Karim A, Nordmann P. EBR-1, a novel Ambler subclass B1 β -lactamase from *Empedobacter brevis*. *Antimicrob Agents Chemother.* 2002;46(10):3223-7.
87. Jiang XW, Cheng H, Huo YY, Xu L, Wu YH, Liu WH, Tao FF, Cui XJ, Zheng BW. Biochemical and genetic characterization of a novel metallo- β -lactamase from marine bacterium *Erythrobacter litoralis* HTCC 2594. *Sci Rep.* 2018;8(1):803.
88. Pollini S, Maradei S, Pecile P, Olivo G, Luzzaro F, Docquier JD, Rossolini GM. FIM-1, a new acquired metallo- β -lactamase from a *Pseudomonas aeruginosa* clinical isolate from Italy. *Antimicrob Agents Chemother.* 2013;57(1):410-6.
89. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a β -lactamase gene, *bla*_{GIM-1}, encoding a new subclass of metallo- β -lactamase. *Antimicrob Agents Chemother.* 2004;48(12):4654-61.
90. Schauer J, Gatermann SG, Eisfeld J, Hans JB, Ziesing S, Schlüter D, Pfennigwerth N. Characterization of GMB-1, a novel metallo- β -lactamase (MBL) found in three different Enterobacterales species. *J Antimicrob Chemother.* 2022;77(5):1247-53.
91. Gudeta DD, Bortolaia V, Pollini S, Docquier JD, Rossolini GM, Amos GC, Wellington EM, Guardabassi L. Expanding the repertoire of carbapenem-hydrolyzing metallo- β -lactamases by functional metagenomic analysis of soil microbiota. *Front Microbiol.* 2016;7:1985.
92. Pfennigwerth N, Lange F, Belmar Campos C, Hentschke M, Gatermann SG, Kaase M. Genetic and biochemical characterization of HMB-1, a novel subclass B1 metallo- β -lactamase found in a *Pseudomonas aeruginosa* clinical isolate. *J Antimicrob Chemother.* 2017;72(4):1068-73.

93. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N. Molecular characterization of an enterobacterial metallo β -lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. *Antimicrob Agents Chemother.* 1994;38(1):71-8.
94. Bellais S, Léotard S, Poirel L, Naas T, Nordmann P. Molecular characterization of a carbapenem-hydrolyzing β -lactamase from *Chryseobacterium (Flavobacterium) indologenes*. *FEMS Microbiol Lett.* 1999;171(2):127-32.
95. Naas T, Bellais S, Nordmann P. Molecular and biochemical characterization of a carbapenem-hydrolysing β -lactamase from *Flavobacterium johnsoniae*. *J Antimicrob Chemother.* 2003;51(2):267-73.
96. Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M, Miyoshi-Akiyama T, Kanamori M, Kirikae T. KHM-1, a novel plasmid-mediated metallo- β -lactamase from a *Citrobacter freundii* clinical isolate. *Antimicrob Agents Chemother.* 2008;52(11):4194-7.
97. Mammeri H, Bellais S, Nordmann P. Chromosome-encoded β -lactamases TUS-1 and MUS-1 from *Myroides odoratus* and *Myroides odoratimimus* (formerly *Flavobacterium odoratum*), new members of the lineage of molecular subclass B1 metalloenzymes. *Antimicrob Agents Chemother.* 2002;46(11):3561-7.
98. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo- β -lactamase gene, *bla_{NDM-1}*, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother.* 2009;53(12):5046-54.

99. Kieffer N, Poirel L, Fournier C, Haltli B, Kerr R, Nordmann P. Characterization of PAN-1, a carbapenem-hydrolyzing class B β -lactamase from the environmental Gram-negative *Pseudobacteriovorax antillogorgiicola*. *Front Microbiol.* 2019;10:1673.
100. Gudeta DD, Bortolaia V, Amos G, Wellington EM, Brandt KK, Poirel L, Nielsen JB, Westh H, Guardabassi L. The soil microbiota harbors a diversity of carbapenem-hydrolyzing β -lactamases of potential clinical relevance. *Antimicrob Agents Chemother.* 2016;60(1):151-60.
101. Poirel L, Héritier C, Nordmann P. Genetic and biochemical characterization of the chromosome-encoded class B β -lactamases from *Shewanella livingstonensis* (SLB-1) and *Shewanella frigidimarina* (SFB-1). *J Antimicrob Chemother.* 2005;55(5):680-5.
102. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, Rossolini GM, Chong Y. Novel acquired metallo- β -lactamase gene, *bla*_{SIM-1}, in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrob Agents Chemother.* 2005;49(11):4485-91.
103. Poirel L, Magalhaes M, Lopes M, Nordmann P. Molecular analysis of metallo- β -lactamase gene *bla*_{SPM-1}-surrounding sequences from disseminated *Pseudomonas aeruginosa* isolates in Recife, Brazil. *Antimicrob Agents Chemother.* 2004;48(4):1406-9.
104. Fang L, Liu Z, Lu Z, Huang R, Xiang R. Identification and characterization of a novel metallo β -lactamase, SZM-1, in Shenzhen Bay, South China. *Front Microbiol.* 2022;13:996834.
105. El Salabi A, Borra PS, Toleman MA, Samuelsen Ø, Walsh TR. Genetic and biochemical characterization of a novel metallo- β -lactamase, TMB-1, from an

Achromobacter xylosoxidans strain isolated in Tripoli, Libya. *Antimicrob Agents Chemother.* 2012;56(5):2241-5.

106. Suzuki S, Matsui M, Suzuki M, Sugita A, Kosuge Y, Kodama N, Ichise Y, Shibayama K. Detection of Tripoli metallo- β -lactamase 2 (TMB-2), a variant of *bla*_{TMB-1}, in clinical isolates of *Acinetobacter* spp. in Japan. *J Antimicrob Chemother.* 2013;68(6):1441-2.

107. Cheng Q, Zheng Z, Ye L, Chen S. Identification of a novel metallo- β -lactamase, VAM-1, in a foodborne *Vibrio alginolyticus* isolate from China. *Antimicrob Agents Chemother.* 2021;65(11):e0112921.

108. Liu M, Zhang W, Peng K, Wang Z, Li R. Identification of a novel plasmid-mediated carbapenemase-encoding gene, *bla*_{VMB-2}, in *Vibrio diabolicus*. *Antimicrob Agents Chemother.* 2021;65(8):e0020621.

109. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini GM. Cloning and characterization of *bla*_{VIM}, a new integron-borne metallo- β -lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother.* 1999;43(7):1584-90.

110. Zheng Z, Cheng Q, Chan EW, Chen S. Genetic and biochemical characterization of VMB-1, a novel metallo- β -lactamase encoded by a conjugative, broad-host range IncC plasmid from *Vibrio* spp. *Adv Biosyst.* 2020;4(3):e1900221.

111. Lu WJ, Hsu PH, Lin HV. A novel cooperative metallo- β -lactamase fold metallohydrolase from pathogen *Vibrio vulnificus* exhibits β -lactam antibiotic-degrading activities. *Antimicrob Agents Chemother.* 2021;65(9):e0032621.

112. Liu S, Zhang L, Feng C, Zhu J, Li A, Zhao J, Zhang Y, Gao M, Shi W, Li Q, Zhang X, Zhang H, Xu T, Lu J, Bao Q. Characterization and identification of a novel chromosome-encoded metallo- β -lactamase WUS-1 in *Myroides albus* P34. *Front Microbiol.* 2022;13:1059997.
113. Kieffer N, Guzmán-Puche J, Poirel L, Kang HJ, Jeon CO, Nordmann P. ZHO-1, an intrinsic MBL from the environmental Gram-negative species *Zhongshania aliphaticivorans*. *J Antimicrob Chemother.* 2019;74(6):1568-71.
114. Massidda O, Rossolini GM, Satta G. The *Aeromonas hydrophila* cphA gene: molecular heterogeneity among class B metallo- β -lactamases. *J Bacteriol.* 1991;173(15):4611-7.
115. Walsh TR, Neville WA, Haran MH, Tolson D, Payne DJ, Bateson JH, MacGowan AP, Bennett PM. Nucleotide and amino acid sequences of the metallo- β -lactamase, ImiS, from *Aeromonas veronii* bv. sobria. *Antimicrob Agents Chemother.* 1998;42(2):436-9.
116. Niumsup P, Simm AM, Nurmahomed K, Walsh TR, Bennett PM, Avison MB. Genetic linkage of the penicillinase gene, *amp*, and *blrAB*, encoding the regulator of β -lactamase expression in *Aeromonas* spp. *J Antimicrob Chemother.* 2003;51(6):1351-8.
117. Poirel L, Palmieri M, Brilhante M, Masseron A, Perreten V, Nordmann P. PFM-like enzymes are a novel family of subclass B2 metallo- β -lactamases from *Pseudomonas synxantha* belonging to the *Pseudomonas fluorescens* complex. *Antimicrob Agents Chemother.* 2020;64(2):e01700-19.
118. Saavedra MJ, Peixe L, Sousa JC, Henriques I, Alves A, Correia A. Sfh-I, a subclass B2 metallo- β -lactamase from a *Serratia fonticola* environmental isolate. *Antimicrob Agents Chemother.* 2003;47(7):2330-3.

119. Mercuri PS, Esposito R, Blétard S, Di Costanzo S, Perilli M, Kerff F, Galleni M. Mutational effects on carbapenem hydrolysis of YEM-1, a new subclass B2 metallo- β -lactamase from *Yersinia mollaretii*. *Antimicrob Agents Chemother.* 2020;64(9):e00105-20.
120. Yong D, Toleman MA, Bell J, Ritchie B, Pratt R, Ryley H, Walsh TR. Genetic and biochemical characterization of an acquired subgroup B3 metallo- β -lactamase gene, *bla_{AIM-1}*, and its unique genetic context in *Pseudomonas aeruginosa* from Australia. *Antimicrob Agents Chemother.* 2012;56(12):6154-9.
121. Stoczko M, Frère JM, Rossolini GM, Docquier JD. Postgenomic scan of metallo- β -lactamase homologues in rhizobacteria: identification and characterization of BJP-1, a subclass B3 ortholog from *Bradyrhizobium japonicum*. *Antimicrob Agents Chemother.* 2006;50(6):1973-81.
122. Au SX, Dzulkifly NS, Muhd Noor ND, Matsumura H, Raja Abdul Rahman RNZ, Normi YM. Dual activity BLEG-1 from *Bacillus lehensis* G1 revealed structural resemblance to B3 metallo- β -lactamase and glyoxalase II: An insight into its enzyme promiscuity and evolutionary divergence. *Int J Mol Sci.* 2021;22(17):9377.
123. Stoczko M, Frère JM, Rossolini GM, Docquier JD. Functional diversity among metallo- β -lactamases: characterization of the CAR-1 enzyme of *Erwinia carotovora*. *Antimicrob Agents Chemother.* 2008;52(7):2473-9.
124. Docquier JD, Pantanella F, Giuliani F, Thaller MC, Amicosante G, Galleni M, Frère JM, Bush K, Rossolini GM. CAU-1, a subclass B3 metallo- β -lactamase of low substrate affinity encoded by an ortholog present in the *Caulobacter crescentus* chromosome. *Antimicrob Agents Chemother.* 2002;46(6):1823-30.

125. Girlich D, Poirel L, Nordmann P. Diversity of naturally occurring Ambler class B metallo- β -lactamases in *Erythrobacter* spp. J Antimicrob Chemother. 2012;67(11):2661-4.
126. Boschi L, Mercuri PS, Riccio ML, Amicosante G, Galleni M, Frère JM, Rossolini GM. The *Legionella (Fluoribacter) gormanii* metallo- β -lactamase: a new member of the highly divergent lineage of molecular-subclass B3 β -lactamases. Antimicrob Agents Chemother. 2000;44(6):1538-43.
127. Bellais S, Aubert D, Naas T, Nordmann P. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β -lactamases in *Chryseobacterium meningosepticum*. Antimicrob Agents Chemother. 2000;44(7):1878-86.
128. Walsh TR, Hall L, Assinder SJ, Nichols WW, Cartwright SJ, MacGowan AP, Bennett PM. Sequence analysis of the L1 metallo- β -lactamase from *Xanthomonas maltophilia*. Biochim Biophys Acta. 1994;1218(2):199-201.
129. Lange F, Pfennigwerth N, Hartl R, Kerschner H, Achleitner D, Gatermann SG, Kaase M. LMB-1, a novel family of class B3 MBLs from an isolate of *Enterobacter cloacae*. J Antimicrob Chemother. 2018;73(9):2331-5.
130. Dabos L, Rodriguez CH, Nastro M, Dortet L, Bonnin RA, Famiglietti A, Iorga BI, Vay C, Naas T. LMB-1 producing *Citrobacter freundii* from Argentina, a novel player in the field of MBLs. Int J Antimicrob Agents. 2020;55(2):105857.
131. Allen HK, Moe LA, Rodbumrer J, Gaarder A, Handelsman J. Functional metagenomics reveals diverse β -lactamases in a remote Alaskan soil. ISME J. 2009;3(2):243-51.

132. Pedroso MM, Selleck C, Enculescu C, Harmer JR, Mitić N, Craig WR, Helweh W, Hugenholtz P, Tyson GW, Tierney DL, Larrabee JA, Schenk G. Characterization of a highly efficient antibiotic-degrading metallo- β -lactamase obtained from an uncultured member of a permafrost community. *Metallomics*. 2017;9(8):1157-68.
133. Lau CH, van Engelen K, Gordon S, Renaud J, Topp E. Novel antibiotic resistance determinants from agricultural soil exposed to antibiotics widely used in human medicine and animal farming. *Appl Environ Microbiol*. 2017;83(16):e00989-17.
134. Miraula M, Schenk G, Mitić N. Promiscuous metallo- β -lactamases: MIM-1 and MIM-2 may play an essential role in quorum sensing networks. *J Inorg Biochem*. 2016;162:366-75.
135. Suzuki M, Suzuki S, Matsui M, Hiraki Y, Kawano F, Shibayama K. A subclass B3 metallo- β -lactamase found in *Pseudomonas alcaligenes*. *J Antimicrob Chemother*. 2014;69(5):1430-2.
136. Yamada K, Yoshizumi A, Nagasawa T, Aoki K, Sasaki M, Murakami H, Morita T, Ishii Y, Tateda K. Molecular and biochemical characterization of novel PAM-like MBL variants, PAM-2 and PAM-3, from clinical isolates of *Pseudomonas tohoni*s. *J Antimicrob Chemother*. 2022;77(9):2414-8.
137. Yamada K, Ishii Y, Tateda K. Biochemical characterization of the subclass B3 metallo- β -lactamase PJM-1 from *Pseudoxanthomonas japonensis*. *Antimicrob Agents Chemother*. 2022;66(9):e0069122.
138. Viana AT, Caetano T, Covas C, Santos T, Mendo S. Environmental superbugs: The case study of *Pedobacter* spp. *Environ Pollut*. 2018;241:1048-55.

139. Thaller MC, Borgianni L, Di Lallo G, Chong Y, Lee K, Dajcs J, Stroman D, Rossolini GM. Metallo- β -lactamase production by *Pseudomonas otitidis*: a species-related trait. *Antimicrob Agents Chemother.* 2011;55(1):118-23.
140. Park KS, Kim TY, Kim JH, Lee JH, Jeon JH, Karim AM, Malik SK, Lee SH. PNGM-1, a novel subclass B3 metallo- β -lactamase from a deep-sea sediment metagenome. *J Glob Antimicrob Resist.* 2018;14:302-5.
141. Salimraj R, Zhang L, Hinchliffe P, Wellington EM, Brem J, Schofield CJ, Gaze WH, Spencer J. Structural and biochemical characterization of Rm3, a subclass B3 metallo- β -lactamase identified from a functional metagenomic study. *Antimicrob Agents Chemother.* 2016;60(10):5828-40.
142. Wilson LA, Knaven EG, Morris MT, Monteiro Pedroso M, Schofield CJ, Brück TB, Boden M, Waite DW, Hugenholtz P, Guddat L, Schenk G. Kinetic and structural characterization of the first B3 metallo- β -lactamase with an active-site glutamic acid. *Antimicrob Agents Chemother.* 2021;65(10):e0093621.
143. Wachino J, Yoshida H, Yamane K, Suzuki S, Matsui M, Yamagishi T, Tsutsui A, Konda T, Shibayama K, Arakawa Y. SMB-1, a novel subclass B3 metallo- β -lactamase, associated with ISCR1 and a class 1 integron, from a carbapenem-resistant *Serratia marcescens* clinical isolate. *Antimicrob Agents Chemother.* 2011;55(11):5143-9.
144. Vella P, Miraula M, Phelan E, Leung EW, Ely F, Ollis DL, McGearry RP, Schenk G, Mitić N. Identification and characterization of an unusual metallo- β -lactamase from *Serratia proteamaculans*. *J Biol Inorg Chem.* 2013;18(7):855-63.

145. Rossolini GM, Condemi MA, Pantanella F, Docquier JD, Amicosante G, Thaller MC. Metallo- β -lactamase producers in environmental microbiota: new molecular class B enzyme in *Janthinobacterium lividum*. *Antimicrob Agents Chemother*. 2001;45(3):837-44.
146. Schenk G, Mitić N, Gahan LR, Ollis DL, McGearry RP, Guddat LW. Binuclear metallohydrolases: complex mechanistic strategies for a simple chemical reaction. *Acc Chem Res*. 2012;45(9):1593-603.
147. Meini MR, Llarrull LI, Vila AJ. Overcoming differences: The catalytic mechanism of metallo- β -lactamases. *FEBS Lett*. 2015;589(22):3419-32.
148. Carfi A, Pares S, Duée E, Galleni M, Duez C, Frère JM, Dideberg O. The 3-D structure of a zinc metallo- β -lactamase from *Bacillus cereus* reveals a new type of protein fold. *EMBO J*. 1995;14(20):4914-21.
149. Ullah JH, Walsh TR, Taylor IA, Emery DC, Verma CS, Gamblin SJ, Spencer J. The crystal structure of the L1 metallo- β -lactamase from *Stenotrophomonas maltophilia* at 1.7 Å resolution. *J Mol Biol*. 1998;284(1):125-36.
150. Garau G, Bebrone C, Anne C, Galleni M, Frère JM, Dideberg O. A metallo- β -lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. *J Mol Biol*. 2005;345(4):785-95.
151. Karsisiotis AI, Damblon CF, Roberts GC. A variety of roles for versatile zinc in metallo- β -lactamases. *Metallomics*. 2014;6(7):1181-97.
152. Estiu G, Suárez D, Merz KM. Quantum mechanical and molecular dynamics simulations of ureases and Zn β -lactamases. *J Comput Chem*. 2006;27(12):1240-62.
153. Lisa MN, Palacios AR, Aitha M, González MM, Moreno DM, Crowder MW, Bonomo RA, Spencer J, Tierney DL, Llarrull LI, Vila AJ. A general reaction mechanism

for carbapenem hydrolysis by mononuclear and binuclear metallo- β -lactamases. *Nat Commun.* 2017;8(1):538.

154. Gervasoni S, Spencer J, Hinchliffe P, Pedretti A, Vairoletti F, Mahler G, Mulholland AJ. A multiscale approach to predict the binding mode of metallo β -lactamase inhibitors. *Proteins.* 2022;90(2):372-84.

155. Bush K, Bradford PA. Epidemiology of β -lactamase-producing pathogens. *Clin Microbiol Rev.* 2020;33(2):e00047-19.

156. Zhao WH, Hu ZQ. Acquired metallo- β -lactamases and their genetic association with class 1 integrons and ISCR elements in Gram-negative bacteria. *Future Microbiol.* 2015;10(5):873-87.

157. Das S. The crisis of carbapenemase-mediated carbapenem resistance across the human-animal-environmental interface in India. *Infect Dis Now.* 2022:in press (10.1016/j.idnow.2022.09.023).

158. Madec JY, Haenni M, Nordmann P, Poirel L. Extended-spectrum β -lactamase/AmpC- and carbapenemase-producing *Enterobacteriaceae* in animals: a threat for humans? *Clin Microbiol Infect.* 2017;23(11):826-33.

159. Roschanski N, Hadziabdic S, Borowiak M, Malorny B, Tenhagen BA, Projahn M, Kaesbohrer A, Guenther S, Szabo I, Roesler U, Fischer J. Detection of VIM-1-producing *Enterobacter cloacae* and *Salmonella enterica* serovars Infantis and Goldcoast at a breeding pig farm in Germany in 2017 and their molecular relationship to former VIM-1-producing *S. infantis* isolates in German livestock production. *mSphere.* 2019;4(3):e00089-19.

160. Cole SD, Peak L, Tyson GH, Reimschuessel R, Ceric O, Rankin SC. New Delhi metallo- β -lactamase-5-producing *Escherichia coli* in companion animals, United States. *Emerg Infect Dis.* 2020;26(2):381-3.
161. Ouchar Mahamat O, Kempf M, Lounnas M, Tidjani A, Hide M, Benavides JA, Carrière C, Bañuls AL, Jean-Pierre H, Ouedraogo AS, Dumont Y, Godreuil S. Epidemiology and prevalence of extended-spectrum β -lactamase- and carbapenemase-producing *Enterobacteriaceae* in humans, animals and the environment in West and Central Africa. *Int J Antimicrob Agents.* 2021;57(1):106203.
162. Kuang X, Zhang Y, Liu J, Yang RS, Qiu ZY, Sun J, Liao XP, Liu YH, Yu Y. Molecular epidemiology of New Delhi metallo- β -lactamase-producing *Escherichia coli* in food-producing animals in China. *Front Microbiol.* 2022;13:912260.
163. Kyung SM, Choi SW, Lim J, Shim S, Kim S, Im YB, Lee NE, Hwang CY, Kim D, Yoo HS. Comparative genomic analysis of plasmids encoding metallo- β -lactamase NDM-5 in Enterobacterales Korean isolates from companion dogs. *Sci Rep.* 2022;12(1):1569.
164. Selmi R, Tayh G, Srairi S, Mamlouk A, Ben Chehida F, Lahmar S, Bouslama M, Daaloul-Jedidi M, Messadi L. Prevalence, risk factors and emergence of extended-spectrum β -lactamase producing-, carbapenem- and colistin-resistant Enterobacterales isolated from wild boar (*Sus scrofa*) in Tunisia. *Microb Pathog.* 2022;163:105385.
165. Ahlstrom CA, Woksepp H, Sandegren L, Mohsin M, Hasan B, Muzyka D, Hernandez J, Aguirre F, Tok A, Söderman J, Olsen B, Ramey AM, Bonnedahl J. Genomically diverse carbapenem resistant *Enterobacteriaceae* from wild birds provide insight into global patterns of spatiotemporal dissemination. *Sci Total Environ.* 2022;824:153632.

166. Hong JS, Song W, Park HM, Oh JY, Chae JC, Han JI, Jeong SH. First detection of New Delhi metallo- β -lactamase-5-producing *Escherichia coli* from companion animals in Korea. *Microb Drug Resist.* 2019;25(3):344-9.
167. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. *Future Microbiol.* 2007;2(5):501-12.
168. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in *Enterobacteriaceae*: here is the storm! *Trends Mol Med.* 2012;18(5):263-72.
169. Mills MC, Lee J. The threat of carbapenem-resistant bacteria in the environment: Evidence of widespread contamination of reservoirs at a global scale. *Environ Pollut.* 2019;255(Pt 1):113143.
170. Dewi D, Götz B, Thomas T. Diversity and genetic basis for carbapenem resistance in a coastal marine environment. *Appl Environ Microbiol.* 2020;86(10):e02939-19.
171. Ranjan R, Thatikonda S. β -Lactam resistance gene NDM-1 in the aquatic environment: A Review. *Curr Microbiol.* 2021;78(10):3634-43.
172. Suzuki Y, Ida M, Kubota H, Ariyoshi T, Murakami K, Kobayashi M, Kato R, Hirai A, Suzuki J, Sadamasu K. Multiple β -lactam resistance gene-carrying plasmid harbored by *Klebsiella quasipneumoniae* isolated from urban sewage in Japan. *mSphere.* 2019;4(5):e00391-19.
173. Sung GH, Kim SH, Park EH, Hwang SN, Kim JD, Kim GR, Kim EY, Jeong J, Kim S, Shin JH. Association of carbapenemase-producing Enterobacterales detected in stream and clinical samples. *Front Microbiol.* 2022;13:923979.
174. Wailan AM, Paterson DL. The spread and acquisition of NDM-1: a multifactorial problem. *Expert Rev Anti Infect Ther.* 2014;12(1):91-115.

175. Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: To combine or not to combine? *Antibiotics (Basel)*. 2019;8(2):38.
176. Asempa TE, Abdelraouf K, Nicolau DP. Activity of β -lactam antibiotics against metallo- β -lactamase-producing Enterobacterales in animal infection models: a current state of affairs. *Antimicrob Agents Chemother*. 2021;65(6):e02271-20.
177. Sato T, Yamawaki K. Cefiderocol: Discovery, chemistry, and *in vivo* profiles of a novel siderophore cephalosporin. *Clin Infect Dis*. 2019;69(Suppl 7):S538-S43.
178. McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: Cefiderocol. *Antimicrob Agents Chemother*. 2021;65(8):e0217120.
179. Noval M, Banoub M, Claeys KC, Heil E. The battle is on: New β -lactams for the treatment of multidrug-resistant Gram-negative organisms. *Curr Infect Dis Rep*. 2020;22(1):1.
180. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β -lactam- β -lactamase inhibitor combinations. *Clin Microbiol Rev*. 2020;34(1):e00115-20.
181. Le Terrier C, Nordmann P, Poirel L. *In vitro* activity of aztreonam in combination with newly developed β -lactamase inhibitors against MDR Enterobacterales and *Pseudomonas aeruginosa* producing metallo- β -lactamases. *J Antimicrob Chemother*. 2022;78(1):101-7.
182. Bush K. A resurgence of β -lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. *Int J Antimicrob Agents*. 2015;46(5):483-93.

183. González MM, Vila AJ. An elusive task: A clinically useful inhibitor of metallo- β -lactamases. In: Supuran CT, Capasso C, editors. Zinc Enzyme Inhibitors: Enzymes from Microorganisms. Cham: Springer International Publishing; 2017. p. 1-34.
184. Buynak JD. β -Lactamase inhibitors: a review of the patent literature (2010 - 2013). *Expert Opin Ther Pat.* 2013;23(11):1469-81.
185. Chen J, Shang X, Hu F, Lao X, Gao X, Zheng H, Yao W. β -Lactamase inhibitors: an update. *Mini Rev Med Chem.* 2013;13(13):1846-61.
186. Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. β -Lactamases and β -lactamase inhibitors in the 21st century. *J Mol Biol.* 2019;431(18):3472-500.
187. Davies DT, Everett M. Designing inhibitors of β -lactamase enzymes to overcome carbapenem resistance in Gram-negative bacteria. *Acc Chem Res.* 2021;54(9):2055-64.
188. Li R, Chen X, Zhou C, Dai QQ, Yang L. Recent advances in β -lactamase inhibitor chemotypes and inhibition modes. *Eur J Med Chem.* 2022;242:114677.
189. Toney JH, Moloughney JG. Metallo- β -lactamase inhibitors: promise for the future? *Curr Opin Investig Drugs.* 2004;5(8):823-6.
190. Fast W, Sutton LD. Metallo- β -lactamase: inhibitors and reporter substrates. *Biochim Biophys Acta.* 2013;1834(8):1648-59.
191. King DT, Strynadka NC. Targeting metallo- β -lactamase enzymes in antibiotic resistance. *Future Med Chem.* 2013;5(11):1243-63.
192. Guo Z, Ma S. Recent advances in the discovery of metallo- β -lactamase inhibitors for β -lactam antibiotic-resistant reversing agents. *Curr Drug Targets.* 2014;15(7):689-702.

193. Somboro AM, Osei Sekyere J, Amoako DG, Essack SY, Bester LA. Diversity and proliferation of metallo- β -lactamases: a clarion call for clinically effective metallo- β -lactamase inhibitors. *Appl Environ Microbiol.* 2018;84(18):e00698-18.
194. McGeary RP, Tan DT, Schenk G. Progress toward inhibitors of metallo- β -lactamases. *Future Med Chem.* 2017;9(7):673-91.
195. Rotondo CM, Wright GD. Inhibitors of metallo- β -lactamases. *Curr Opin Microbiol.* 2017;39:96-105.
196. Wang P, Cheng J, Liu CC, Tang K, Xu F, Yu Z, Yu B, Chang J. The development of new small-molecule inhibitors targeting bacterial metallo- β -lactamases. *Curr Top Med Chem.* 2018;18(10):834-43.
197. Ju LC, Cheng Z, Fast W, Bonomo RA, Crowder MW. The continuing challenge of metallo- β -lactamase inhibition: Mechanism matters. *Trends Pharmacol Sci.* 2018;39(7):635-47.
198. Linciano P, Cendron L, Gianquinto E, Spyrakis F, Tondi D. Ten years with New Delhi metallo- β -lactamase-1 (NDM-1): From structural insights to inhibitor design. *ACS Infect Dis.* 2019;5(1):9-34.
199. Shi C, Chen J, Kang X, Shen X, Lao X, Zheng H. Approaches for the discovery of metallo- β -lactamase inhibitors: A review. *Chem Biol Drug Des.* 2019;94(2):1427-40.
200. Kaushik A, Kaushik M, Lather V, Dua JS. Recent review on subclass B1 metallo- β -lactamases inhibitors: Sword for antimicrobial resistance. *Curr Drug Targets.* 2019;20(7):756-62.

201. Reddy N, Shungube M, Arvidsson PI, Baijnath S, Kruger HG, Govender T, Naicker T. A 2018-2019 patent review of metallo β -lactamase inhibitors. *Expert Opin Ther Pat.* 2020;30(7):541-55.
202. Nagulapalli Venkata KC, Ellebrecht M, Tripathi SK. Efforts towards the inhibitor design for New Delhi metallo- β -lactamase (NDM-1). *Eur J Med Chem.* 2021;225:113747.
203. Wang T, Xu K, Zhao L, Tong R, Xiong L, Shi J. Recent research and development of NDM-1 inhibitors. *Eur J Med Chem.* 2021;223:113667.
204. Li X, Zhao J, Zhang B, Duan X, Jiao J, Wu W, Zhou Y, Wang H. Drug development concerning metallo- β -lactamases in Gram-negative bacteria. *Front Microbiol.* 2022;13:959107.
205. Mojica MF, Rossi MA, Vila AJ, Bonomo RA. The urgent need for metallo- β -lactamase inhibitors: an unattended global threat. *Lancet Infect Dis.* 2022;22(1):e28-e34.
206. Gu X, Zheng M, Chen L, Li H. The development of New Delhi metallo- β -lactamase-1 inhibitors since 2018. *Microbiol Res.* 2022;261:127079.
207. Kurosaki H, Yamaguchi Y, Higashi T, Soga K, Matsueda S, Yumoto H, Misumi S, Yamagata Y, Arakawa Y, Goto M. Irreversible inhibition of metallo- β -lactamase (IMP-1) by 3-(3-mercaptopropionylsulfanyl)propionic acid pentafluorophenyl ester. *Angew Chem Int Ed Engl.* 2005;44(25):3861-4.
208. Spencer J, Walsh TR. A new approach to the inhibition of metallo- β -lactamases. *Angew Chem Int Ed Engl.* 2006;45(7):1022-6.
209. González MM, Kosmopoulou M, Mojica MF, Castillo V, Hinchliffe P, Pettinati I, Brem J, Schofield CJ, Mahler G, Bonomo RA, Llarrull LI, Spencer J, Vila AJ.

Bisthiazolidines: A substrate-mimicking scaffold as an inhibitor of the NDM-1 carbapenemase. *ACS Infect Dis.* 2015;1(11):544-54.

210. Hinchliffe P, González MM, Mojica MF, González JM, Castillo V, Saiz C, Kosmopoulou M, Tooke CL, Llarrull LI, Mahler G, Bonomo RA, Vila AJ, Spencer J. Cross-class metallo- β -lactamase inhibition by bisthiazolidines reveals multiple binding modes. *Proc Natl Acad Sci U S A.* 2016;113(26):E3745-54.

211. Mojica MF, Mahler SG, Bethel CR, Taracila MA, Kosmopoulou M, Papp-Wallace KM, Llarrull LI, Wilson BM, Marshall SH, Wallace CJ, Villegas MV, Harris ME, Vila AJ, Spencer J, Bonomo RA. Exploring the role of residue 228 in substrate and inhibitor recognition by VIM metallo- β -lactamases. *Biochemistry.* 2015;54(20):3183-96.

212. Saiz C, Villamil V, González MM, Rossi MA, Martínez L, Suescun L, Vila AJ, Mahler G. Enantioselective synthesis of new oxazolidinylthiazolidines as enzyme inhibitors. *Tetrahedron Asymmetry.* 2017;28(1):110-7.

213. Hinchliffe P, Moreno DM, Rossi MA, Mojica MF, Martinez V, Villamil V, Spellberg B, Drusano GL, Banchio C, Mahler G, Bonomo RA, Vila AJ, Spencer J. 2-Mercaptomethyl thiazolidines (MMTZs) inhibit all metallo- β -lactamase classes by maintaining a conserved binding mode. *ACS Infect Dis.* 2021;7(9):2697-706.

214. Rossi MA, Martinez V, Hinchliffe P, Mojica MF, Castillo V, Moreno DM, Smith R, Spellberg B, Drusano GL, Banchio C, Bonomo RA, Spencer J, Vila AJ, Mahler G. 2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo- β -lactamases. *Chem Sci.* 2021;12(8):2898-908.

215. Everett M, Sprynski N, Coelho A, Castandet J, Bayet M, Bougnon J, Lozano C, Davies DT, Leiris S, Zalacain M, Morrissey I, Magnet S, Holden K, Warn P, De Luca F,

Docquier JD, Lemonnier M. Discovery of a novel metallo- β -lactamase inhibitor that potentiates meropenem activity against carbapenem-resistant *Enterobacteriaceae*. *Antimicrob Agents Chemother*. 2018;62(5):e00074-18.

216. Leiris S, Coelho A, Castandet J, Bayet M, Lozano C, Bougnon J, Bousquet J, Everett M, Lemonnier M, Sprynski N, Zalacain M, Pallin TD, Cramp MC, Jennings N, Raphy G, Jones MW, Pattipati R, Shankar B, Sivasubrahmanyam R, Soodhagani AK, Juventhala RR, Pottabathini N, Pothukanuri S, Benvenuti M, Pozzi C, Mangani S, De Luca F, Cerboni G, Docquier JD, Davies DT. SAR studies leading to the identification of a novel series of metallo- β -lactamase inhibitors for the treatment of carbapenem-resistant *Enterobacteriaceae* infections that display efficacy in an animal infection model. *ACS Infect Dis*. 2019;5(1):131-40.

217. Davies DT, Leiris S, Sprynski N, Castandet J, Lozano C, Bousquet J, Zalacain M, Vasa S, Dasari PK, Pattipati R, Vempala N, Gujjewar S, Godi S, Jallala R, Sathyap RR, Darshanoju NA, Ravu VR, Juventhala RR, Pottabathini N, Sharma S, Pothukanuri S, Holden K, Warn P, Marcoccia F, Benvenuti M, Pozzi C, Mangani S, Docquier JD, Lemonnier M, Everett M. ANT2681: SAR studies leading to the identification of a metallo- β -lactamase inhibitor with potential for clinical use in combination with meropenem for the treatment of infections caused by NDM-producing *Enterobacteriaceae*. *ACS Infect Dis*. 2020;6(9):2419-30.

218. Zalacain M, Lozano C, Llanos A, Sprynski N, Valmont T, De Piano C, Davies D, Leiris S, Sable C, Ledoux A, Morrissey I, Lemonnier M, Everett M. Novel specific metallo- β -lactamase inhibitor ANT2681 restores meropenem activity to clinically effective

levels against NDM-positive Enterobacterales. *Antimicrob Agents Chemother.* 2021;65(6):e00203-21.

219. Bahr G, González LJ, Vila AJ. Metallo- β -lactamases and a tug-of-war for the available zinc at the host-pathogen interface. *Curr Opin Chem Biol.* 2022;66:102103.

220. King AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC, Walsh TR, Coombes BK, Wright GD. Aspergillomarasmine A overcomes metallo- β -lactamase antibiotic resistance. *Nature.* 2014;510(7506):503-6.

221. von Nussbaum F, Schiffer G. Aspergillomarasmine A, an inhibitor of bacterial metallo- β -lactamases conferring *bla*_{NDM} and *bla*_{VIM} resistance. *Angew Chem Int Ed Engl.* 2014;53(44):11696-8.

222. Rotondo CM, Sychantha D, Koteva K, Wright GD. Suppression of β -lactam resistance by aspergillomarasmine A is influenced by both the metallo- β -lactamase target and the antibiotic partner. *Antimicrob Agents Chemother.* 2020;64(4):e01386-19.

223. Bergstrom A, Katko A, Adkins Z, Hill J, Cheng Z, Burnett M, Yang H, Aitha M, Mehaffey MR, Brodbelt JS, Tehrani K, Martin NI, Bonomo RA, Page RC, Tierney DL, Fast W, Wright GD, Crowder MW. Probing the interaction of aspergillomarasmine A with metallo- β -lactamases NDM-1, VIM-2, and IMP-7. *ACS Infect Dis.* 2018;4(2):135-45.

224. Sychantha D, Rotondo CM, Tehrani K, Martin NI, Wright GD. Aspergillomarasmine A inhibits metallo- β -lactamases by selectively sequestering Zn(2). *J Biol Chem.* 2021;297(2):100918.

225. Albu SA, Koteva K, King AM, Al-Karmi S, Wright GD, Capretta A. Total synthesis of aspergillomarasmine A and related compounds: A sulfamidate approach

enables exploration of structure-activity relationships. *Angew Chem Int Ed Engl.* 2016;55(42):13259-62.

226. Koteva K, King AM, Capretta A, Wright GD. Total synthesis and activity of the metallo- β -lactamase inhibitor aspergillomarasmine A. *Angew Chem Int Ed Engl.* 2016;55(6):2210-2.

227. Liao D, Yang S, Wang J, Zhang J, Hong B, Wu F, Lei X. Total synthesis and structural reassignment of aspergillomarasmine A. *Angew Chem Int Ed Engl.* 2016;55(13):4291-5.

228. Zhang J, Wang S, Bai Y, Guo Q, Zhou J, Lei X. Total syntheses of natural metallophores staphylopine and aspergillomarasmine A. *J Org Chem.* 2017;82(24):13643-8.

229. Zhang J, Wang S, Wei Q, Guo Q, Bai Y, Yang S, Song F, Zhang L, Lei X. Synthesis and biological evaluation of aspergillomarasmine A derivatives as novel NDM-1 inhibitor to overcome antibiotics resistance. *Bioorg Med Chem.* 2017;25(19):5133-41.

230. Koteva K, Sychantha D, Rotondo CM, Hobson C, Britten JF, Wright GD. Three-dimensional structure and optimization of the metallo- β -lactamase inhibitor aspergillomarasmine A. *ACS Omega.* 2022;7(5):4170-84.

231. Tehrani K, Fu H, Bröchle NC, Mashayekhi V, Prats Luján A, van Haren MJ, Poelarends GJ, Martin NI. Aminocarboxylic acids related to aspergillomarasmine A (AMA) and ethylenediamine-*N,N'*-disuccinic acid (EDDS) are strong zinc-binders and inhibitors of the metallo- β -lactamase NDM-1. *Chem Commun (Camb).* 2020;56(20):3047-9.

232. Chen AY, Thomas CA, Thomas PW, Yang K, Cheng Z, Fast W, Crowder MW, Cohen SM. Iminodiacetic acid as a novel metal-binding pharmacophore for New Delhi metallo- β -lactamase inhibitor development. *ChemMedChem*. 2020;15(14):1272-82.
233. Sevaille L, Gavara L, Bebrone C, De Luca F, Nauton L, Achard M, Mercuri P, Tanfoni S, Borgianni L, Guyon C, Lonjon P, Turan-Zitouni G, Dzieciolowski J, Becker K, Bénard L, Condon C, Maillard L, Martinez J, Frère JM, Dideberg O, Galleni M, Docquier JD, Hernandez JF. 1,2,4-Triazole-3-thione compounds as inhibitors of dizinc metallo- β -lactamases. *ChemMedChem*. 2017;12(12):972-85.
234. Gavara L, Sevaille L, De Luca F, Mercuri P, Bebrone C, Feller G, Legru A, Cerboni G, Tanfoni S, Baud D, Cutolo G, Bestgen B, Chelini G, Verdirosa F, Sannio F, Pozzi C, Benvenuti M, Kwapien K, Fischer M, Becker K, Frère JM, Mangani S, Gresh N, Berthomieu D, Galleni M, Docquier JD, Hernandez JF. 4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo- β -lactamase inhibitors. *Eur J Med Chem*. 2020;208:112720.
235. Gavara L, Verdirosa F, Legru A, Mercuri PS, Nauton L, Sevaille L, Feller G, Berthomieu D, Sannio F, Marcoccia F, Tanfoni S, De Luca F, Gresh N, Galleni M, Docquier JD, Hernandez JF. 4-(*N*-Alkyl- and -acyl-amino)-1,2,4-triazole-3-thione analogs as metallo- β -lactamase inhibitors: Impact of 4-linker on potency and spectrum of inhibition. *Biomolecules*. 2020;10(8):1094.
236. Gavara L, Legru A, Verdirosa F, Sevaille L, Nauton L, Corsica G, Mercuri PS, Sannio F, Feller G, Coulon R, De Luca F, Cerboni G, Tanfoni S, Chelini G, Galleni M, Docquier JD, Hernandez JF. 4-Alkyl-1,2,4-triazole-3-thione analogues as metallo- β -lactamase inhibitors. *Bioorg Chem*. 2021;113:105024.

237. Legru A, Verdirosa F, Hernandez JF, Tassone G, Sannio F, Benvenuti M, Conde PA, Bossis G, Thomas CA, Crowder MW, Dillenberger M, Becker K, Pozzi C, Mangani S, Docquier JD, Gavara L. 1,2,4-Triazole-3-thione compounds with a 4-ethyl alkyl/aryl sulfide substituent are broad-spectrum metallo- β -lactamase inhibitors with re-sensitization activity. *Eur J Med Chem.* 2021;226:113873.
238. Gavara L, Verdirosa F, Seville L, Legru A, Corsica G, Nauton L, Sandra Mercuri P, Sannio F, De Luca F, Hadjadj M, Cerboni G, Vo Hoang Y, Licznar-Fajardo P, Galleni M, Docquier JD, Hernandez JF. 1,2,4-Triazole-3-thione analogues with an arylalkyl group at position 4 as metallo- β -lactamase inhibitors. *Bioorg Med Chem.* 2022;72:116964.
239. Verdirosa F, Gavara L, Seville L, Tassone G, Corsica G, Legru A, Feller G, Chelini G, Mercuri PS, Tanfoni S, Sannio F, Benvenuti M, Cerboni G, De Luca F, Bouajila E, Vo Hoang Y, Licznar-Fajardo P, Galleni M, Pozzi C, Mangani S, Docquier JD, Hernandez JF. 1,2,4-Triazole-3-thione analogues with a 2-ethylbenzoic acid at position 4 as VIM-type metallo- β -lactamase inhibitors. *ChemMedChem.* 2022;17(7):e202100699.
240. Kwapien K, Gavara L, Docquier JD, Berthomieu D, Hernandez JF, Gresh N. Intermolecular interactions of the extended recognition site of VIM-2 metallo- β -lactamase with 1,2,4-triazole-3-thione inhibitors. Validations of a polarizable molecular mechanics potential by *ab initio* QC. *J Comput Chem.* 2021;42(2):86-106.
241. Legru A, Verdirosa F, Vo-Hoang Y, Tassone G, Vascon F, Thomas CA, Sannio F, Corsica G, Benvenuti M, Feller G, Coulon R, Marcoccia F, Devente SR, Bouajila E, Piveteau C, Leroux F, Deprez-Poulain R, Deprez B, Licznar-Fajardo P, Crowder MW, Cendron L, Pozzi C, Mangani S, Docquier JD, Hernandez JF, Gavara L. Optimization of 1,2,4-triazole-3-thiones toward broad-spectrum metallo- β -lactamase inhibitors showing

potent synergistic activity on VIM- and NDM-1-producing clinical isolates. *J Med Chem.* 2022;65(24):16392-419.

242. Chen C, Yang KW. Structure-based design of covalent inhibitors targeting metallo- β -lactamases. *Eur J Med Chem.* 2020;203:112573.

243. Su J, Liu J, Chen C, Zhang Y, Yang K. Ebsulfur as a potent scaffold for inhibition and labelling of New Delhi metallo- β -lactamase-1 *in vitro* and *in vivo*. *Bioorg Chem.* 2019;84:192-201.

244. Mehaffey MR, Ahn YC, Rivera DD, Thomas PW, Cheng Z, Crowder MW, Pratt RF, Fast W, Brodbelt JS. Elusive structural changes of New Delhi metallo- β -lactamase revealed by ultraviolet photodissociation mass spectrometry. *Chem Sci.* 2020;11(33):8999-9010.

245. Thomas PW, Cammarata M, Brodbelt JS, Monzingo AF, Pratt RF, Fast W. A lysine-targeted affinity label for serine- β -lactamase also covalently modifies New Delhi metallo- β -lactamase-1 (NDM-1). *Biochemistry.* 2019;58(25):2834-43.

246. Kang PW, Su JP, Sun LY, Gao H, Yang KW. 3-Bromopyruvate as a potent covalently reversible inhibitor of New Delhi metallo- β -lactamase-1 (NDM-1). *Eur J Pharm Sci.* 2020;142:105161.

247. Yue K, Xu C, Wang Z, Liu W, Liu C, Xu X, Xing Y, Chen S, Li X, Wan S. 1,2-Isoselenazol-3(2*H*)-one derivatives as NDM-1 inhibitors displaying synergistic antimicrobial effects with meropenem on NDM-1 producing clinical isolates. *Bioorg Chem.* 2022;129:106153.

248. Chen C, Yang KW, Wu LY, Li JQ, Sun LY. Disulfiram as a potent metallo- β -lactamase inhibitor with dual functional mechanisms. *Chem Commun (Camb)*. 2020;56(18):2755-8.
249. Tehrani K, Wade N, Mashayekhi V, Bröchle NC, Jespers W, Voskuil K, Pesce D, van Haren MJ, van Westen GJP, Martin NI. Novel cephalosporin conjugates display potent and selective inhibition of imipenemase-type metallo- β -lactamases. *J Med Chem*. 2021;64(13):9141-51.
250. van Haren MJ, Tehrani K, Kotsogianni I, Wade N, Bröchle NC, Mashayekhi V, Martin NI. Cephalosporin prodrug inhibitors overcome metallo- β -lactamase driven antibiotic resistance. *Chemistry*. 2021;27(11):3806-11.
251. Tian H, Wang Y, Dai Y, Mao A, Zhou W, Cao X, Deng H, Lu H, Ding L, Shen H, Wang X. A cephalosporin-tripodalamine conjugate inhibits metallo- β -lactamase with high efficacy and low toxicity. *Antimicrob Agents Chemother*. 2022:e0035222.
252. Chen C, Oelschlaeger P, Wang D, Xu H, Wang Q, Wang C, Zhao A, Yang KW. Structure and mechanism-guided design of dual serine/metallo-carbapenemase inhibitors. *J Med Chem*. 2022;65(8):5954-74.
253. Romero E, Oueslati S, Benchekroun M, D'Hollander ACA, Ventre S, Vijayakumar K, Minard C, Exilie C, Tlili L, Retailleau P, Zavala A, Elisée E, Selwa E, Nguyen LA, Pruvost A, Naas T, Iorga BI, Dodd RH, Cariou K. Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β -lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D). *Eur J Med Chem*. 2021;219:113418.

254. Santucci M, Spyraakis F, Cross S, Quotadamo A, Farina D, Tondi D, De Luca F, Docquier JD, Prieto AI, Ibacache C, Blázquez J, Venturelli A, Cruciani G, Costi MP. Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo- β -lactamases. *Sci Rep.* 2017;7(1):17716.
255. Linciano P, Gianquinto E, Montanari M, Maso L, Bellio P, Cebrián-Sastre E, Celenza G, Blázquez J, Cendron L, Spyraakis F, Tondi D. 4-Amino-1,2,4-triazole-3-thione as a promising scaffold for the inhibition of serine and metallo- β -lactamases. *Pharmaceuticals (Basel).* 2020;13(3):52.
256. Krajnc A, Brem J, Hinchliffe P, Calvopiña K, Panduwawala TD, Lang PA, Kamps J, Tyrrell JM, Widlake E, Saward BG, Walsh TR, Spencer J, Schofield CJ. Bicyclic boronate VNRX-5133 inhibits metallo- and serine- β -lactamases. *J Med Chem.* 2019;62(18):8544-56.
257. Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle DM. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo- β -lactamases, restores activity of cefepime in Enterobacterales and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2020;64(3):e01963-19.
258. Liu B, Trout REL, Chu GH, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, Xerri L, Burns CJ. Discovery of taniborbactam (VNRX-5133): A broad-spectrum serine- and metallo- β -lactamase inhibitor for carbapenem-resistant bacterial infections. *J Med Chem.* 2020;63(6):2789-801.

259. Hecker SJ, Reddy KR, Lomovskaya O, Griffith DC, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Parkinson J, Totrov M, Boyer SH, Glinka TW, Pemberton OA, Chen Y, Dudley MN. Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo- β -lactamases. *J Med Chem.* 2020;63(14):7491-507.
260. Lomovskaya O, Nelson K, Rubio-Aparicio D, Tsivkovski R, Sun D, Dudley MN. Impact of intrinsic resistance mechanisms on potency of QPX7728, a new ultrabroad-spectrum β -lactamase inhibitor of serine and metallo- β -lactamases in *Enterobacteriaceae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2020;64(6):e00552-20.
261. Lomovskaya O, Rubio-Aparicio D, Nelson K, Sun D, Tsivkovski R, Castanheira M, Lindley J, Loutit J, Dudley M. *In vitro* activity of the ultrabroad-spectrum β -lactamase inhibitor QPX7728 in combination with multiple β -lactam antibiotics against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2021;65(6):e00210-21.
262. Lomovskaya O, Tsivkovski R, Nelson K, Rubio-Aparicio D, Sun D, Totrov M, Dudley MN. Spectrum of β -lactamase inhibition by the cyclic boronate QPX7728, an ultrabroad-spectrum β -lactamase inhibitor of serine and metallo- β -lactamases: Enhancement of activity of multiple antibiotics against isogenic strains expressing single β -lactamases. *Antimicrob Agents Chemother.* 2020;64(6):e00212-20.
263. Nelson K, Rubio-Aparicio D, Sun D, Dudley M, Lomovskaya O. *In vitro* activity of the ultrabroad-spectrum- β -lactamase inhibitor QPX7728 against carbapenem-resistant Enterobacterales with varying intrinsic and acquired resistance mechanisms. *Antimicrob Agents Chemother.* 2020;64(8):e00757-20.

264. Nelson K, Rubio-Aparicio D, Tsivkovski R, Sun D, Totrov M, Dudley M, Lomovskaya O. *In vitro* activity of the ultra-broad-spectrum β -lactamase inhibitor QPX7728 in combination with meropenem against clinical isolates of carbapenem-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2020;64(11):e01406-20.
265. Sabet M, Tarazi Z, Griffith DC. *In vivo* activity of QPX7728, an ultrabroad-spectrum β -lactamase inhibitor, in combination with β -lactams against carbapenem-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2020;64(11):e01267-20.
266. Tsivkovski R, Totrov M, Lomovskaya O. Biochemical characterization of QPX7728, a new ultrabroad-spectrum β -lactamase inhibitor of serine and metallo- β -lactamases. *Antimicrob Agents Chemother.* 2020;64(6):e00130-20.
267. Lomovskaya O, Tsivkovski R, Sun D, Reddy R, Totrov M, Hecker S, Griffith D, Loutit J, Dudley M. QPX7728, an ultra-broad-spectrum β -lactamase inhibitor for intravenous and oral therapy: Overview of biochemical and microbiological characteristics. *Front Microbiol.* 2021;12:697180.
268. Lomovskaya O, Rubio-Aparicio D, Tsivkovski R, Loutit J, Dudley M. The ultrabroad-spectrum β -lactamase inhibitor QPX7728 restores the potency of multiple oral β -lactam antibiotics against β -lactamase-producing strains of resistant Enterobacterales. *Antimicrob Agents Chemother.* 2022;66(2):e0216821.